# PeptideScanner evidence objects: Oxytocin

Every published version of the records placed with Oxytocin, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/oxytocin.json. Selected public evidence only; not medical advice.

- Objects: 82
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00790062-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT00790062

> PeptideScanner retained ClinicalTrials.gov record NCT00790062 at 2026-11-16T00:59:19.138Z. Its registry update date was 2016-04-08, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct00790062-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-04-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00790062-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct00790062-oxytocin-v1
- Content SHA-256: `88f4d36ada182f21e999b4cfec720f975b7af5674d6bd59034f1ecefe7b04250`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00790062 ([`ctg-observation-nct00790062-2016-04-08-7fd85d675afe`](#source-ctg-observation-nct00790062-2016-04-08-7fd85d675afe))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00790062 at 2026-11-16T00:59:19.138Z. Its registry update date was 2016-04-08, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct00790062-2016-04-08-7fd85d675afe`](#source-ctg-observation-nct00790062-2016-04-08-7fd85d675afe))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00790062 at 2026-11-16T00:59:19.138Z. Its registry update date was 2016-04-08, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct00790062-2016-04-08-7fd85d675afe`](#source-ctg-observation-nct00790062-2016-04-08-7fd85d675afe))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00790062-2016-04-08-7fd85d675afe`](#source-ctg-observation-nct00790062-2016-04-08-7fd85d675afe))

### Sources

<a id="source-ctg-observation-nct00790062-2016-04-08-7fd85d675afe"></a>
- **ClinicalTrials.gov record NCT00790062 · retained source version 2016-04-08:7fd85d675afea436a0e0ba315435702d4d25721b0bafbc3b162070b114b97cf9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00790062) (`ctg-observation-nct00790062-2016-04-08-7fd85d675afe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00790062." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct00790062-oxytocin-v1 SHA-256: 88f4d36ada182f21e999b4cfec720f975b7af5674d6bd59034f1ecefe7b04250.

---

<a id="clinicaltrials-gov-nct00906347-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT00906347

> PeptideScanner retained ClinicalTrials.gov record NCT00906347 at 2026-11-16T00:59:19.138Z. Its registry update date was 2012-11-15, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct00906347-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00906347-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct00906347-oxytocin-v1
- Content SHA-256: `244fc59498142167508cb85cf0c33f00c5c136b85dd50aee2934a6c617bfca93`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00906347 ([`ctg-observation-nct00906347-2012-11-15-a195f10f3455`](#source-ctg-observation-nct00906347-2012-11-15-a195f10f3455))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00906347 at 2026-11-16T00:59:19.138Z. Its registry update date was 2012-11-15, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct00906347-2012-11-15-a195f10f3455`](#source-ctg-observation-nct00906347-2012-11-15-a195f10f3455))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00906347 at 2026-11-16T00:59:19.138Z. Its registry update date was 2012-11-15, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct00906347-2012-11-15-a195f10f3455`](#source-ctg-observation-nct00906347-2012-11-15-a195f10f3455))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00906347-2012-11-15-a195f10f3455`](#source-ctg-observation-nct00906347-2012-11-15-a195f10f3455))

### Sources

<a id="source-ctg-observation-nct00906347-2012-11-15-a195f10f3455"></a>
- **ClinicalTrials.gov record NCT00906347 · retained source version 2012-11-15:a195f10f34551b96615567421134c58e7b9bc1c4159e599600084ce4155d41eb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00906347) (`ctg-observation-nct00906347-2012-11-15-a195f10f3455`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00906347." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct00906347-oxytocin-v1 SHA-256: 244fc59498142167508cb85cf0c33f00c5c136b85dd50aee2934a6c617bfca93.

---

<a id="clinicaltrials-gov-nct00919802-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT00919802

> PeptideScanner retained ClinicalTrials.gov record NCT00919802 at 2026-11-16T00:59:19.138Z. Its registry update date was 2017-05-23, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct00919802-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-05-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00919802-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct00919802-oxytocin-v1
- Content SHA-256: `702780ccb8c67a8d37634f4d3714b4643d542e2ca00d826c1bba32228c927a65`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00919802 ([`ctg-observation-nct00919802-2017-05-23-06f07271bf0c`](#source-ctg-observation-nct00919802-2017-05-23-06f07271bf0c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00919802 at 2026-11-16T00:59:19.138Z. Its registry update date was 2017-05-23, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct00919802-2017-05-23-06f07271bf0c`](#source-ctg-observation-nct00919802-2017-05-23-06f07271bf0c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00919802 at 2026-11-16T00:59:19.138Z. Its registry update date was 2017-05-23, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct00919802-2017-05-23-06f07271bf0c`](#source-ctg-observation-nct00919802-2017-05-23-06f07271bf0c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00919802-2017-05-23-06f07271bf0c`](#source-ctg-observation-nct00919802-2017-05-23-06f07271bf0c))

### Sources

<a id="source-ctg-observation-nct00919802-2017-05-23-06f07271bf0c"></a>
- **ClinicalTrials.gov record NCT00919802 · retained source version 2017-05-23:06f07271bf0c894d645f77f7afdfbe0bfc318bc31ef695360625689eacbe19c5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00919802) (`ctg-observation-nct00919802-2017-05-23-06f07271bf0c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00919802." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct00919802-oxytocin-v1 SHA-256: 702780ccb8c67a8d37634f4d3714b4643d542e2ca00d826c1bba32228c927a65.

---

<a id="clinicaltrials-gov-nct01614093-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT01614093

> PeptideScanner retained ClinicalTrials.gov record NCT01614093 at 2026-11-16T00:59:19.138Z. Its registry update date was 2019-08-28, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct01614093-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-08-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01614093-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct01614093-oxytocin-v1
- Content SHA-256: `47c24b098ee3af9fb3a14ff77dabf1cc4da999fa20cc7db83a41d69e7e822a81`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01614093 ([`ctg-observation-nct01614093-2019-08-28-4cd2e364cc69`](#source-ctg-observation-nct01614093-2019-08-28-4cd2e364cc69))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01614093 at 2026-11-16T00:59:19.138Z. Its registry update date was 2019-08-28, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct01614093-2019-08-28-4cd2e364cc69`](#source-ctg-observation-nct01614093-2019-08-28-4cd2e364cc69))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01614093 at 2026-11-16T00:59:19.138Z. Its registry update date was 2019-08-28, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct01614093-2019-08-28-4cd2e364cc69`](#source-ctg-observation-nct01614093-2019-08-28-4cd2e364cc69))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01614093-2019-08-28-4cd2e364cc69`](#source-ctg-observation-nct01614093-2019-08-28-4cd2e364cc69))

### Sources

<a id="source-ctg-observation-nct01614093-2019-08-28-4cd2e364cc69"></a>
- **ClinicalTrials.gov record NCT01614093 · retained source version 2019-08-28:4cd2e364cc69f9e78c389b849f95e0c67a601f0da53031b53d2c21cf99340b11** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01614093) (`ctg-observation-nct01614093-2019-08-28-4cd2e364cc69`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01614093." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct01614093-oxytocin-v1 SHA-256: 47c24b098ee3af9fb3a14ff77dabf1cc4da999fa20cc7db83a41d69e7e822a81.

---

<a id="clinicaltrials-gov-nct01829516-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT01829516

> PeptideScanner retained ClinicalTrials.gov record NCT01829516 at 2026-11-16T00:59:19.138Z. Its registry update date was 2016-07-27, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct01829516-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-07-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01829516-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct01829516-oxytocin-v1
- Content SHA-256: `d70cc02520190087d60b880d5cce8f60a6959cd9e55d0cbb568addc95cd3e85f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01829516 ([`ctg-observation-nct01829516-2016-07-27-a39ed0884220`](#source-ctg-observation-nct01829516-2016-07-27-a39ed0884220))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01829516 at 2026-11-16T00:59:19.138Z. Its registry update date was 2016-07-27, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct01829516-2016-07-27-a39ed0884220`](#source-ctg-observation-nct01829516-2016-07-27-a39ed0884220))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01829516 at 2026-11-16T00:59:19.138Z. Its registry update date was 2016-07-27, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct01829516-2016-07-27-a39ed0884220`](#source-ctg-observation-nct01829516-2016-07-27-a39ed0884220))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01829516-2016-07-27-a39ed0884220`](#source-ctg-observation-nct01829516-2016-07-27-a39ed0884220))

### Sources

<a id="source-ctg-observation-nct01829516-2016-07-27-a39ed0884220"></a>
- **ClinicalTrials.gov record NCT01829516 · retained source version 2016-07-27:a39ed08842204de0edfaa2bf2e7fc460719e7397f5033ab6c7030b333336ff82** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01829516) (`ctg-observation-nct01829516-2016-07-27-a39ed0884220`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01829516." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct01829516-oxytocin-v1 SHA-256: d70cc02520190087d60b880d5cce8f60a6959cd9e55d0cbb568addc95cd3e85f.

---

<a id="clinicaltrials-gov-nct02150954-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT02150954

> PeptideScanner retained ClinicalTrials.gov record NCT02150954 at 2026-11-16T00:59:19.138Z. Its registry update date was 2023-10-26, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct02150954-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-10-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02150954-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct02150954-oxytocin-v1
- Content SHA-256: `95b53d509e5a717e634e26ab4da6218367c4ab9aeadab22f85611571fa628576`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02150954 ([`ctg-observation-nct02150954-2023-10-26-3dce088181be`](#source-ctg-observation-nct02150954-2023-10-26-3dce088181be))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02150954 at 2026-11-16T00:59:19.138Z. Its registry update date was 2023-10-26, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct02150954-2023-10-26-3dce088181be`](#source-ctg-observation-nct02150954-2023-10-26-3dce088181be))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02150954 at 2026-11-16T00:59:19.138Z. Its registry update date was 2023-10-26, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct02150954-2023-10-26-3dce088181be`](#source-ctg-observation-nct02150954-2023-10-26-3dce088181be))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02150954-2023-10-26-3dce088181be`](#source-ctg-observation-nct02150954-2023-10-26-3dce088181be))

### Sources

<a id="source-ctg-observation-nct02150954-2023-10-26-3dce088181be"></a>
- **ClinicalTrials.gov record NCT02150954 · retained source version 2023-10-26:3dce088181be900252817487cef383ef91cc0baa29d6c3c57a9662f28b617ddd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02150954) (`ctg-observation-nct02150954-2023-10-26-3dce088181be`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02150954." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct02150954-oxytocin-v1 SHA-256: 95b53d509e5a717e634e26ab4da6218367c4ab9aeadab22f85611571fa628576.

---

<a id="clinicaltrials-gov-nct02273115-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT02273115

> PeptideScanner retained ClinicalTrials.gov record NCT02273115 at 2026-11-16T00:59:19.138Z. Its registry update date was 2017-07-02, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct02273115-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-07-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02273115-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct02273115-oxytocin-v1
- Content SHA-256: `99fe96328308f01540dcac031e80a6735da684bdc673dcdcfe4f1bcaa77a3562`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02273115 ([`ctg-observation-nct02273115-2017-07-02-8d2f3d5112c0`](#source-ctg-observation-nct02273115-2017-07-02-8d2f3d5112c0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02273115 at 2026-11-16T00:59:19.138Z. Its registry update date was 2017-07-02, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct02273115-2017-07-02-8d2f3d5112c0`](#source-ctg-observation-nct02273115-2017-07-02-8d2f3d5112c0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02273115 at 2026-11-16T00:59:19.138Z. Its registry update date was 2017-07-02, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct02273115-2017-07-02-8d2f3d5112c0`](#source-ctg-observation-nct02273115-2017-07-02-8d2f3d5112c0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02273115-2017-07-02-8d2f3d5112c0`](#source-ctg-observation-nct02273115-2017-07-02-8d2f3d5112c0))

### Sources

<a id="source-ctg-observation-nct02273115-2017-07-02-8d2f3d5112c0"></a>
- **ClinicalTrials.gov record NCT02273115 · retained source version 2017-07-02:8d2f3d5112c0fe79f1fa4c8156e775983b8e235840991073dc0be161071349d6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02273115) (`ctg-observation-nct02273115-2017-07-02-8d2f3d5112c0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02273115." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct02273115-oxytocin-v1 SHA-256: 99fe96328308f01540dcac031e80a6735da684bdc673dcdcfe4f1bcaa77a3562.

---

<a id="clinicaltrials-gov-nct02487797-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT02487797

> PeptideScanner retained ClinicalTrials.gov record NCT02487797 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-02-11, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct02487797-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-02-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02487797-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct02487797-oxytocin-v1
- Content SHA-256: `2c38b09072384b6930ea7d01b597f644b2dd52986d89e5ec94f2104a4ef6c306`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02487797 ([`ctg-observation-nct02487797-2022-02-11-12c874255369`](#source-ctg-observation-nct02487797-2022-02-11-12c874255369))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02487797 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-02-11, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct02487797-2022-02-11-12c874255369`](#source-ctg-observation-nct02487797-2022-02-11-12c874255369))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02487797 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-02-11, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct02487797-2022-02-11-12c874255369`](#source-ctg-observation-nct02487797-2022-02-11-12c874255369))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02487797-2022-02-11-12c874255369`](#source-ctg-observation-nct02487797-2022-02-11-12c874255369))

### Sources

<a id="source-ctg-observation-nct02487797-2022-02-11-12c874255369"></a>
- **ClinicalTrials.gov record NCT02487797 · retained source version 2022-02-11:12c87425536938a3e94cadfe7fb0213ec9bd2853f7811081eeef10b277a9260e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02487797) (`ctg-observation-nct02487797-2022-02-11-12c874255369`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02487797." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct02487797-oxytocin-v1 SHA-256: 2c38b09072384b6930ea7d01b597f644b2dd52986d89e5ec94f2104a4ef6c306.

---

<a id="clinicaltrials-gov-nct02505984-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT02505984

> PeptideScanner retained ClinicalTrials.gov record NCT02505984 at 2026-11-16T00:59:19.138Z. Its registry update date was 2025-02-25, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct02505984-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-02-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02505984-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct02505984-oxytocin-v1
- Content SHA-256: `2f73e4fbe688a0f8f81494899995e80372b9216c062bedbd7dd658f1f35e03f3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02505984 ([`ctg-observation-nct02505984-2025-02-25-ba2af36f94b7`](#source-ctg-observation-nct02505984-2025-02-25-ba2af36f94b7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02505984 at 2026-11-16T00:59:19.138Z. Its registry update date was 2025-02-25, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct02505984-2025-02-25-ba2af36f94b7`](#source-ctg-observation-nct02505984-2025-02-25-ba2af36f94b7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02505984 at 2026-11-16T00:59:19.138Z. Its registry update date was 2025-02-25, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct02505984-2025-02-25-ba2af36f94b7`](#source-ctg-observation-nct02505984-2025-02-25-ba2af36f94b7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02505984-2025-02-25-ba2af36f94b7`](#source-ctg-observation-nct02505984-2025-02-25-ba2af36f94b7))

### Sources

<a id="source-ctg-observation-nct02505984-2025-02-25-ba2af36f94b7"></a>
- **ClinicalTrials.gov record NCT02505984 · retained source version 2025-02-25:ba2af36f94b77f220805b39c62fe306d0b89aed52b0abe0465542114e26d499c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02505984) (`ctg-observation-nct02505984-2025-02-25-ba2af36f94b7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02505984." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct02505984-oxytocin-v1 SHA-256: 2f73e4fbe688a0f8f81494899995e80372b9216c062bedbd7dd658f1f35e03f3.

---

<a id="clinicaltrials-gov-nct02508103-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT02508103

> PeptideScanner retained ClinicalTrials.gov record NCT02508103 at 2026-11-16T00:59:19.138Z. Its registry update date was 2017-06-27, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct02508103-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-06-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02508103-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct02508103-oxytocin-v1
- Content SHA-256: `66c5aff32d3bce7f2ff4fcbe4152d4c56f98a53dde1c7ea1f62d52e587f6b2f4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02508103 ([`ctg-observation-nct02508103-2017-06-27-6dadf1a4107d`](#source-ctg-observation-nct02508103-2017-06-27-6dadf1a4107d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02508103 at 2026-11-16T00:59:19.138Z. Its registry update date was 2017-06-27, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct02508103-2017-06-27-6dadf1a4107d`](#source-ctg-observation-nct02508103-2017-06-27-6dadf1a4107d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02508103 at 2026-11-16T00:59:19.138Z. Its registry update date was 2017-06-27, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct02508103-2017-06-27-6dadf1a4107d`](#source-ctg-observation-nct02508103-2017-06-27-6dadf1a4107d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02508103-2017-06-27-6dadf1a4107d`](#source-ctg-observation-nct02508103-2017-06-27-6dadf1a4107d))

### Sources

<a id="source-ctg-observation-nct02508103-2017-06-27-6dadf1a4107d"></a>
- **ClinicalTrials.gov record NCT02508103 · retained source version 2017-06-27:6dadf1a4107d356636c910b77d602842ab54a1381b08e5acadae3eb13c6253d9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02508103) (`ctg-observation-nct02508103-2017-06-27-6dadf1a4107d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02508103." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct02508103-oxytocin-v1 SHA-256: 66c5aff32d3bce7f2ff4fcbe4152d4c56f98a53dde1c7ea1f62d52e587f6b2f4.

---

<a id="clinicaltrials-gov-nct02595749-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT02595749

> PeptideScanner retained ClinicalTrials.gov record NCT02595749 at 2026-11-16T00:59:19.138Z. Its registry update date was 2021-11-15, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct02595749-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02595749-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct02595749-oxytocin-v1
- Content SHA-256: `6bcc371e099f83f579a01d18abd12a4c8e85c66d1e061114817ea58a17cb7f49`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02595749 ([`ctg-observation-nct02595749-2021-11-15-f7676783a5a9`](#source-ctg-observation-nct02595749-2021-11-15-f7676783a5a9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02595749 at 2026-11-16T00:59:19.138Z. Its registry update date was 2021-11-15, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct02595749-2021-11-15-f7676783a5a9`](#source-ctg-observation-nct02595749-2021-11-15-f7676783a5a9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02595749 at 2026-11-16T00:59:19.138Z. Its registry update date was 2021-11-15, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct02595749-2021-11-15-f7676783a5a9`](#source-ctg-observation-nct02595749-2021-11-15-f7676783a5a9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02595749-2021-11-15-f7676783a5a9`](#source-ctg-observation-nct02595749-2021-11-15-f7676783a5a9))

### Sources

<a id="source-ctg-observation-nct02595749-2021-11-15-f7676783a5a9"></a>
- **ClinicalTrials.gov record NCT02595749 · retained source version 2021-11-15:f7676783a5a9b2957c87214936e63a2fe9b8c8f92f79b48d3cc979230308cd88** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02595749) (`ctg-observation-nct02595749-2021-11-15-f7676783a5a9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02595749." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct02595749-oxytocin-v1 SHA-256: 6bcc371e099f83f579a01d18abd12a4c8e85c66d1e061114817ea58a17cb7f49.

---

<a id="clinicaltrials-gov-nct02918864-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT02918864

> PeptideScanner retained ClinicalTrials.gov record NCT02918864 at 2026-11-16T00:59:19.138Z. Its registry update date was 2024-04-05, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct02918864-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-04-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02918864-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct02918864-oxytocin-v1
- Content SHA-256: `e7294d0eaa1d43c41532d44c57e442e28b73bb3d06c5c3cd8661f14fad2f3685`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02918864 ([`ctg-observation-nct02918864-2024-04-05-65c3715794e0`](#source-ctg-observation-nct02918864-2024-04-05-65c3715794e0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02918864 at 2026-11-16T00:59:19.138Z. Its registry update date was 2024-04-05, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct02918864-2024-04-05-65c3715794e0`](#source-ctg-observation-nct02918864-2024-04-05-65c3715794e0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02918864 at 2026-11-16T00:59:19.138Z. Its registry update date was 2024-04-05, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct02918864-2024-04-05-65c3715794e0`](#source-ctg-observation-nct02918864-2024-04-05-65c3715794e0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02918864-2024-04-05-65c3715794e0`](#source-ctg-observation-nct02918864-2024-04-05-65c3715794e0))

### Sources

<a id="source-ctg-observation-nct02918864-2024-04-05-65c3715794e0"></a>
- **ClinicalTrials.gov record NCT02918864 · retained source version 2024-04-05:65c3715794e007eafef745e7e331fc9d327005aeea2e4db502701c5514f4d6fe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02918864) (`ctg-observation-nct02918864-2024-04-05-65c3715794e0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02918864." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct02918864-oxytocin-v1 SHA-256: e7294d0eaa1d43c41532d44c57e442e28b73bb3d06c5c3cd8661f14fad2f3685.

---

<a id="clinicaltrials-gov-nct03138252-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT03138252

> PeptideScanner retained ClinicalTrials.gov record NCT03138252 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-05-04, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct03138252-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-05-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03138252-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct03138252-oxytocin-v1
- Content SHA-256: `a8a4b566f7df88f3050ddef94101d320bba0501c36dff9caf398e9f4788524ba`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03138252 ([`ctg-observation-nct03138252-2022-05-04-f54b6ff77506`](#source-ctg-observation-nct03138252-2022-05-04-f54b6ff77506))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03138252 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-05-04, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct03138252-2022-05-04-f54b6ff77506`](#source-ctg-observation-nct03138252-2022-05-04-f54b6ff77506))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03138252 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-05-04, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct03138252-2022-05-04-f54b6ff77506`](#source-ctg-observation-nct03138252-2022-05-04-f54b6ff77506))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03138252-2022-05-04-f54b6ff77506`](#source-ctg-observation-nct03138252-2022-05-04-f54b6ff77506))

### Sources

<a id="source-ctg-observation-nct03138252-2022-05-04-f54b6ff77506"></a>
- **ClinicalTrials.gov record NCT03138252 · retained source version 2022-05-04:f54b6ff7750696fff453fce9f84f4b7366e51a303ab95f2604ca4dd03c172559** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03138252) (`ctg-observation-nct03138252-2022-05-04-f54b6ff77506`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03138252." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct03138252-oxytocin-v1 SHA-256: a8a4b566f7df88f3050ddef94101d320bba0501c36dff9caf398e9f4788524ba.

---

<a id="clinicaltrials-gov-nct03140488-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT03140488

> PeptideScanner retained ClinicalTrials.gov record NCT03140488 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-12-20, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct03140488-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-12-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03140488-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct03140488-oxytocin-v1
- Content SHA-256: `80b3acdf5e5d7513948f70dcc4945c5c7ca78dcc450f8c45a9ed7e0f2f6ccf26`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03140488 ([`ctg-observation-nct03140488-2022-12-20-59894ba685dd`](#source-ctg-observation-nct03140488-2022-12-20-59894ba685dd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03140488 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-12-20, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct03140488-2022-12-20-59894ba685dd`](#source-ctg-observation-nct03140488-2022-12-20-59894ba685dd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03140488 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-12-20, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct03140488-2022-12-20-59894ba685dd`](#source-ctg-observation-nct03140488-2022-12-20-59894ba685dd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03140488-2022-12-20-59894ba685dd`](#source-ctg-observation-nct03140488-2022-12-20-59894ba685dd))

### Sources

<a id="source-ctg-observation-nct03140488-2022-12-20-59894ba685dd"></a>
- **ClinicalTrials.gov record NCT03140488 · retained source version 2022-12-20:59894ba685ddbb330f25f2a05afd8cd45c05dc75a00affc1a4401bb7f3e8aff9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03140488) (`ctg-observation-nct03140488-2022-12-20-59894ba685dd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03140488." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct03140488-oxytocin-v1 SHA-256: 80b3acdf5e5d7513948f70dcc4945c5c7ca78dcc450f8c45a9ed7e0f2f6ccf26.

---

<a id="clinicaltrials-gov-nct03463993-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT03463993

> PeptideScanner retained ClinicalTrials.gov record NCT03463993 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-06-01, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct03463993-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-06-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03463993-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct03463993-oxytocin-v1
- Content SHA-256: `af85b71a5845102a77d08a1e81b4d4ba662143ff137181e4001f1a5089930549`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03463993 ([`ctg-observation-nct03463993-2022-06-01-cab0bf43811d`](#source-ctg-observation-nct03463993-2022-06-01-cab0bf43811d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03463993 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-06-01, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct03463993-2022-06-01-cab0bf43811d`](#source-ctg-observation-nct03463993-2022-06-01-cab0bf43811d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03463993 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-06-01, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct03463993-2022-06-01-cab0bf43811d`](#source-ctg-observation-nct03463993-2022-06-01-cab0bf43811d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03463993-2022-06-01-cab0bf43811d`](#source-ctg-observation-nct03463993-2022-06-01-cab0bf43811d))

### Sources

<a id="source-ctg-observation-nct03463993-2022-06-01-cab0bf43811d"></a>
- **ClinicalTrials.gov record NCT03463993 · retained source version 2022-06-01:cab0bf43811d93988595c500ef5c020c5c537e0bd86ca6006c74643c8eca8439** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03463993) (`ctg-observation-nct03463993-2022-06-01-cab0bf43811d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03463993." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct03463993-oxytocin-v1 SHA-256: af85b71a5845102a77d08a1e81b4d4ba662143ff137181e4001f1a5089930549.

---

<a id="clinicaltrials-gov-nct03846505-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT03846505

> PeptideScanner retained ClinicalTrials.gov record NCT03846505 at 2026-11-16T00:59:19.138Z. Its registry update date was 2025-02-21, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct03846505-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-02-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03846505-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct03846505-oxytocin-v1
- Content SHA-256: `3b2de9a716539b76c8e847b5c0875c67aec23576c728f3fc60ee4d6b63e7f812`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03846505 ([`ctg-observation-nct03846505-2025-02-21-0616241bdec0`](#source-ctg-observation-nct03846505-2025-02-21-0616241bdec0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03846505 at 2026-11-16T00:59:19.138Z. Its registry update date was 2025-02-21, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct03846505-2025-02-21-0616241bdec0`](#source-ctg-observation-nct03846505-2025-02-21-0616241bdec0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03846505 at 2026-11-16T00:59:19.138Z. Its registry update date was 2025-02-21, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct03846505-2025-02-21-0616241bdec0`](#source-ctg-observation-nct03846505-2025-02-21-0616241bdec0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03846505-2025-02-21-0616241bdec0`](#source-ctg-observation-nct03846505-2025-02-21-0616241bdec0))

### Sources

<a id="source-ctg-observation-nct03846505-2025-02-21-0616241bdec0"></a>
- **ClinicalTrials.gov record NCT03846505 · retained source version 2025-02-21:0616241bdec06f3f4bfd182670fc30f69fc26d75821d95575c20f3c2e6b064cc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03846505) (`ctg-observation-nct03846505-2025-02-21-0616241bdec0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03846505." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct03846505-oxytocin-v1 SHA-256: 3b2de9a716539b76c8e847b5c0875c67aec23576c728f3fc60ee4d6b63e7f812.

---

<a id="clinicaltrials-gov-nct03899961-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT03899961

> PeptideScanner retained ClinicalTrials.gov record NCT03899961 at 2026-11-16T00:59:19.138Z. Its registry update date was 2026-02-10, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct03899961-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03899961-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct03899961-oxytocin-v1
- Content SHA-256: `bd229be6f7d1f91cb7ec3c14b7edc93cc7789b7367ced9477451b75d247f9f62`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03899961 ([`ctg-observation-nct03899961-2026-02-10-b3fa4edd75e6`](#source-ctg-observation-nct03899961-2026-02-10-b3fa4edd75e6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03899961 at 2026-11-16T00:59:19.138Z. Its registry update date was 2026-02-10, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct03899961-2026-02-10-b3fa4edd75e6`](#source-ctg-observation-nct03899961-2026-02-10-b3fa4edd75e6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03899961 at 2026-11-16T00:59:19.138Z. Its registry update date was 2026-02-10, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct03899961-2026-02-10-b3fa4edd75e6`](#source-ctg-observation-nct03899961-2026-02-10-b3fa4edd75e6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03899961-2026-02-10-b3fa4edd75e6`](#source-ctg-observation-nct03899961-2026-02-10-b3fa4edd75e6))

### Sources

<a id="source-ctg-observation-nct03899961-2026-02-10-b3fa4edd75e6"></a>
- **ClinicalTrials.gov record NCT03899961 · retained source version 2026-02-10:b3fa4edd75e64131a748b1353159be2bc37ceeb3a6effe7e6a6fbadc888eba36** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03899961) (`ctg-observation-nct03899961-2026-02-10-b3fa4edd75e6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03899961." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct03899961-oxytocin-v1 SHA-256: bd229be6f7d1f91cb7ec3c14b7edc93cc7789b7367ced9477451b75d247f9f62.

---

<a id="clinicaltrials-gov-nct03929367-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT03929367

> PeptideScanner retained ClinicalTrials.gov record NCT03929367 at 2026-11-16T00:59:19.138Z. Its registry update date was 2021-05-13, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct03929367-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-05-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03929367-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct03929367-oxytocin-v1
- Content SHA-256: `b44ff4910c16278990d6ce4afae24c43ea8f25808e1d5a43cb6e23bbbc09b830`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03929367 ([`ctg-observation-nct03929367-2021-05-13-4521e528c23e`](#source-ctg-observation-nct03929367-2021-05-13-4521e528c23e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03929367 at 2026-11-16T00:59:19.138Z. Its registry update date was 2021-05-13, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct03929367-2021-05-13-4521e528c23e`](#source-ctg-observation-nct03929367-2021-05-13-4521e528c23e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03929367 at 2026-11-16T00:59:19.138Z. Its registry update date was 2021-05-13, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct03929367-2021-05-13-4521e528c23e`](#source-ctg-observation-nct03929367-2021-05-13-4521e528c23e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03929367-2021-05-13-4521e528c23e`](#source-ctg-observation-nct03929367-2021-05-13-4521e528c23e))

### Sources

<a id="source-ctg-observation-nct03929367-2021-05-13-4521e528c23e"></a>
- **ClinicalTrials.gov record NCT03929367 · retained source version 2021-05-13:4521e528c23e0bd899011aca67a1c909a7e4a957994ad93d0f33b26b438adc7b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03929367) (`ctg-observation-nct03929367-2021-05-13-4521e528c23e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03929367." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct03929367-oxytocin-v1 SHA-256: b44ff4910c16278990d6ce4afae24c43ea8f25808e1d5a43cb6e23bbbc09b830.

---

<a id="clinicaltrials-gov-nct03935399-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT03935399

> PeptideScanner retained ClinicalTrials.gov record NCT03935399 at 2026-11-16T00:59:19.138Z. Its registry update date was 2021-04-05, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct03935399-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-04-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03935399-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct03935399-oxytocin-v1
- Content SHA-256: `de2c792733940216dbc6b34e8cfcf8fa8c13461d009fde5e6a134c81b4721226`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03935399 ([`ctg-observation-nct03935399-2021-04-05-ae72c7a94ad6`](#source-ctg-observation-nct03935399-2021-04-05-ae72c7a94ad6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03935399 at 2026-11-16T00:59:19.138Z. Its registry update date was 2021-04-05, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct03935399-2021-04-05-ae72c7a94ad6`](#source-ctg-observation-nct03935399-2021-04-05-ae72c7a94ad6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03935399 at 2026-11-16T00:59:19.138Z. Its registry update date was 2021-04-05, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct03935399-2021-04-05-ae72c7a94ad6`](#source-ctg-observation-nct03935399-2021-04-05-ae72c7a94ad6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03935399-2021-04-05-ae72c7a94ad6`](#source-ctg-observation-nct03935399-2021-04-05-ae72c7a94ad6))

### Sources

<a id="source-ctg-observation-nct03935399-2021-04-05-ae72c7a94ad6"></a>
- **ClinicalTrials.gov record NCT03935399 · retained source version 2021-04-05:ae72c7a94ad6451d9385c3ce38b89db4f180b73958fbe75be2b2694e48a1be1e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03935399) (`ctg-observation-nct03935399-2021-04-05-ae72c7a94ad6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03935399." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct03935399-oxytocin-v1 SHA-256: de2c792733940216dbc6b34e8cfcf8fa8c13461d009fde5e6a134c81b4721226.

---

<a id="clinicaltrials-gov-nct04028765-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT04028765

> PeptideScanner retained ClinicalTrials.gov record NCT04028765 at 2026-11-16T00:59:19.138Z. Its registry update date was 2024-04-30, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct04028765-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-04-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04028765-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct04028765-oxytocin-v1
- Content SHA-256: `acc599c11a66c524e3bb5f1f5f4b2c4a45e65094c4bf8ce8c648960ed2bf6097`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04028765 ([`ctg-observation-nct04028765-2024-04-30-489b8821f936`](#source-ctg-observation-nct04028765-2024-04-30-489b8821f936))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04028765 at 2026-11-16T00:59:19.138Z. Its registry update date was 2024-04-30, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct04028765-2024-04-30-489b8821f936`](#source-ctg-observation-nct04028765-2024-04-30-489b8821f936))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04028765 at 2026-11-16T00:59:19.138Z. Its registry update date was 2024-04-30, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct04028765-2024-04-30-489b8821f936`](#source-ctg-observation-nct04028765-2024-04-30-489b8821f936))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04028765-2024-04-30-489b8821f936`](#source-ctg-observation-nct04028765-2024-04-30-489b8821f936))

### Sources

<a id="source-ctg-observation-nct04028765-2024-04-30-489b8821f936"></a>
- **ClinicalTrials.gov record NCT04028765 · retained source version 2024-04-30:489b8821f936b88ce8e32737e28ef9b9c07827fe810091ecac86bb2536cb901e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04028765) (`ctg-observation-nct04028765-2024-04-30-489b8821f936`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04028765." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct04028765-oxytocin-v1 SHA-256: acc599c11a66c524e3bb5f1f5f4b2c4a45e65094c4bf8ce8c648960ed2bf6097.

---

<a id="clinicaltrials-gov-nct04105998-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT04105998

> PeptideScanner retained ClinicalTrials.gov record NCT04105998 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-11-10, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct04105998-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-11-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04105998-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct04105998-oxytocin-v1
- Content SHA-256: `fcc728d8c63a975583496b2f2399b971ef3537eb81ecfa2a04ced3fa2a96dd7b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04105998 ([`ctg-observation-nct04105998-2022-11-10-b6d1239a2011`](#source-ctg-observation-nct04105998-2022-11-10-b6d1239a2011))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04105998 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-11-10, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct04105998-2022-11-10-b6d1239a2011`](#source-ctg-observation-nct04105998-2022-11-10-b6d1239a2011))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04105998 at 2026-11-16T00:59:19.138Z. Its registry update date was 2022-11-10, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct04105998-2022-11-10-b6d1239a2011`](#source-ctg-observation-nct04105998-2022-11-10-b6d1239a2011))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04105998-2022-11-10-b6d1239a2011`](#source-ctg-observation-nct04105998-2022-11-10-b6d1239a2011))

### Sources

<a id="source-ctg-observation-nct04105998-2022-11-10-b6d1239a2011"></a>
- **ClinicalTrials.gov record NCT04105998 · retained source version 2022-11-10:b6d1239a20112f81c3c4ed42f46e9b347bad9a340ac5ad1702eb3a242c762c55** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04105998) (`ctg-observation-nct04105998-2022-11-10-b6d1239a2011`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04105998." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct04105998-oxytocin-v1 SHA-256: fcc728d8c63a975583496b2f2399b971ef3537eb81ecfa2a04ced3fa2a96dd7b.

---

<a id="clinicaltrials-gov-nct04228289-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT04228289

> PeptideScanner retained ClinicalTrials.gov record NCT04228289 at 2026-11-16T00:59:19.138Z. Its registry update date was 2026-03-11, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct04228289-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04228289-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct04228289-oxytocin-v1
- Content SHA-256: `0b0297e65679f01ee96f59d3b39936ec35d0739ce57ca4b02d2dab7855654103`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04228289 ([`ctg-observation-nct04228289-2026-03-11-73e0e400fdc0`](#source-ctg-observation-nct04228289-2026-03-11-73e0e400fdc0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04228289 at 2026-11-16T00:59:19.138Z. Its registry update date was 2026-03-11, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct04228289-2026-03-11-73e0e400fdc0`](#source-ctg-observation-nct04228289-2026-03-11-73e0e400fdc0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04228289 at 2026-11-16T00:59:19.138Z. Its registry update date was 2026-03-11, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct04228289-2026-03-11-73e0e400fdc0`](#source-ctg-observation-nct04228289-2026-03-11-73e0e400fdc0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04228289-2026-03-11-73e0e400fdc0`](#source-ctg-observation-nct04228289-2026-03-11-73e0e400fdc0))

### Sources

<a id="source-ctg-observation-nct04228289-2026-03-11-73e0e400fdc0"></a>
- **ClinicalTrials.gov record NCT04228289 · retained source version 2026-03-11:73e0e400fdc0184c1d9c066ee657252a15fc212149f808f563e324441bc1f5ec** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04228289) (`ctg-observation-nct04228289-2026-03-11-73e0e400fdc0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04228289." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct04228289-oxytocin-v1 SHA-256: 0b0297e65679f01ee96f59d3b39936ec35d0739ce57ca4b02d2dab7855654103.

---

<a id="clinicaltrials-gov-nct05326776-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT05326776

> PeptideScanner retained ClinicalTrials.gov record NCT05326776 at 2026-11-16T00:59:19.138Z. Its registry update date was 2024-12-31, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct05326776-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-12-31
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05326776-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct05326776-oxytocin-v1
- Content SHA-256: `9846034f3f99c8fed45532aff910f1e25e8478f97d218b79847b9d5a0b37ce34`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05326776 ([`ctg-observation-nct05326776-2024-12-31-605219d0bc98`](#source-ctg-observation-nct05326776-2024-12-31-605219d0bc98))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05326776 at 2026-11-16T00:59:19.138Z. Its registry update date was 2024-12-31, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct05326776-2024-12-31-605219d0bc98`](#source-ctg-observation-nct05326776-2024-12-31-605219d0bc98))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05326776 at 2026-11-16T00:59:19.138Z. Its registry update date was 2024-12-31, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct05326776-2024-12-31-605219d0bc98`](#source-ctg-observation-nct05326776-2024-12-31-605219d0bc98))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05326776-2024-12-31-605219d0bc98`](#source-ctg-observation-nct05326776-2024-12-31-605219d0bc98))

### Sources

<a id="source-ctg-observation-nct05326776-2024-12-31-605219d0bc98"></a>
- **ClinicalTrials.gov record NCT05326776 · retained source version 2024-12-31:605219d0bc9833a0e0bbc014fc8ae5e415bbc0f38937f404006f22a947b1f6a9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05326776) (`ctg-observation-nct05326776-2024-12-31-605219d0bc98`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05326776." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct05326776-oxytocin-v1 SHA-256: 9846034f3f99c8fed45532aff910f1e25e8478f97d218b79847b9d5a0b37ce34.

---

<a id="clinicaltrials-gov-nct05782816-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT05782816

> PeptideScanner retained ClinicalTrials.gov record NCT05782816 at 2026-11-16T00:59:19.138Z. Its registry update date was 2026-01-09, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct05782816-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05782816-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct05782816-oxytocin-v1
- Content SHA-256: `be85dbc11b669063056acc26bbef105d1c482b9559a5f7f68ade38b154e8843a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05782816 ([`ctg-observation-nct05782816-2026-01-09-e52d08e5dd08`](#source-ctg-observation-nct05782816-2026-01-09-e52d08e5dd08))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05782816 at 2026-11-16T00:59:19.138Z. Its registry update date was 2026-01-09, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct05782816-2026-01-09-e52d08e5dd08`](#source-ctg-observation-nct05782816-2026-01-09-e52d08e5dd08))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05782816 at 2026-11-16T00:59:19.138Z. Its registry update date was 2026-01-09, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct05782816-2026-01-09-e52d08e5dd08`](#source-ctg-observation-nct05782816-2026-01-09-e52d08e5dd08))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05782816-2026-01-09-e52d08e5dd08`](#source-ctg-observation-nct05782816-2026-01-09-e52d08e5dd08))

### Sources

<a id="source-ctg-observation-nct05782816-2026-01-09-e52d08e5dd08"></a>
- **ClinicalTrials.gov record NCT05782816 · retained source version 2026-01-09:e52d08e5dd08a44e8d47a5750440ea1227beee86e97b695f4eb6ee0e6f9b70bc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05782816) (`ctg-observation-nct05782816-2026-01-09-e52d08e5dd08`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05782816." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct05782816-oxytocin-v1 SHA-256: be85dbc11b669063056acc26bbef105d1c482b9559a5f7f68ade38b154e8843a.

---

<a id="clinicaltrials-gov-nct05929339-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT05929339

> PeptideScanner retained ClinicalTrials.gov record NCT05929339 at 2026-11-16T00:59:19.138Z. Its registry update date was 2025-10-28, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct05929339-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-10-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05929339-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct05929339-oxytocin-v1
- Content SHA-256: `6b2b8cd00cb303fb5369777789d9badd7530e46fecf92d1bd710e98c83df6b24`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05929339 ([`ctg-observation-nct05929339-2025-10-28-347aabba4f43`](#source-ctg-observation-nct05929339-2025-10-28-347aabba4f43))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05929339 at 2026-11-16T00:59:19.138Z. Its registry update date was 2025-10-28, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct05929339-2025-10-28-347aabba4f43`](#source-ctg-observation-nct05929339-2025-10-28-347aabba4f43))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05929339 at 2026-11-16T00:59:19.138Z. Its registry update date was 2025-10-28, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct05929339-2025-10-28-347aabba4f43`](#source-ctg-observation-nct05929339-2025-10-28-347aabba4f43))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05929339-2025-10-28-347aabba4f43`](#source-ctg-observation-nct05929339-2025-10-28-347aabba4f43))

### Sources

<a id="source-ctg-observation-nct05929339-2025-10-28-347aabba4f43"></a>
- **ClinicalTrials.gov record NCT05929339 · retained source version 2025-10-28:347aabba4f43870f7e7a429c2a24df9fd05d1fa84a4584f4f25c0361db87a3ed** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05929339) (`ctg-observation-nct05929339-2025-10-28-347aabba4f43`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05929339." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct05929339-oxytocin-v1 SHA-256: 6b2b8cd00cb303fb5369777789d9badd7530e46fecf92d1bd710e98c83df6b24.

---

<a id="clinicaltrials-gov-nct06285396-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT06285396

> PeptideScanner retained ClinicalTrials.gov record NCT06285396 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct06285396-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06285396-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct06285396-oxytocin-v1
- Content SHA-256: `07bbb0ceb7585b614b9c6d0a83b7da4655d7b069ec280627bbe7d020e768f080`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06285396 ([`ctg-observation-nct06285396-2026-11-16-f5989fc9f860`](#source-ctg-observation-nct06285396-2026-11-16-f5989fc9f860))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06285396 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct06285396-2026-11-16-f5989fc9f860`](#source-ctg-observation-nct06285396-2026-11-16-f5989fc9f860))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06285396 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct06285396-2026-11-16-f5989fc9f860`](#source-ctg-observation-nct06285396-2026-11-16-f5989fc9f860))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06285396-2026-11-16-f5989fc9f860`](#source-ctg-observation-nct06285396-2026-11-16-f5989fc9f860))

### Sources

<a id="source-ctg-observation-nct06285396-2026-11-16-f5989fc9f860"></a>
- **ClinicalTrials.gov record NCT06285396 · retained source version 2026-11-16:f5989fc9f860cc3a55d9ac0669083d805e1cb81b08e127dc60c8207ebad5055d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06285396) (`ctg-observation-nct06285396-2026-11-16-f5989fc9f860`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06285396." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct06285396-oxytocin-v1 SHA-256: 07bbb0ceb7585b614b9c6d0a83b7da4655d7b069ec280627bbe7d020e768f080.

---

<a id="clinicaltrials-gov-nct06930391-oxytocin-v1"></a>

## ClinicalTrials.gov record NCT06930391

> PeptideScanner retained ClinicalTrials.gov record NCT06930391 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was oxytocin.

- Evidence object: `story:clinicaltrials-gov-nct06930391-oxytocin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06930391-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct06930391-oxytocin-v1
- Content SHA-256: `08e7f2d62c12a480b739b8902b696d7d7f8b038dbe7d4488f3f8a0f0fb15d097`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06930391 ([`ctg-observation-nct06930391-2026-11-13-9ee7a7e02419`](#source-ctg-observation-nct06930391-2026-11-13-9ee7a7e02419))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06930391 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct06930391-2026-11-13-9ee7a7e02419`](#source-ctg-observation-nct06930391-2026-11-13-9ee7a7e02419))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06930391 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was oxytocin. ([`ctg-observation-nct06930391-2026-11-13-9ee7a7e02419`](#source-ctg-observation-nct06930391-2026-11-13-9ee7a7e02419))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06930391-2026-11-13-9ee7a7e02419`](#source-ctg-observation-nct06930391-2026-11-13-9ee7a7e02419))

### Sources

<a id="source-ctg-observation-nct06930391-2026-11-13-9ee7a7e02419"></a>
- **ClinicalTrials.gov record NCT06930391 · retained source version 2026-11-13:9ee7a7e0241922e1be10b470db04a9db9b6910b22dd95bebfe990952c056e474** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06930391) (`ctg-observation-nct06930391-2026-11-13-9ee7a7e02419`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06930391." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#clinicaltrials-gov-nct06930391-oxytocin-v1 SHA-256: 08e7f2d62c12a480b739b8902b696d7d7f8b038dbe7d4488f3f8a0f0fb15d097.

---

<a id="fda-drugs-anda077453-v1"></a>

## Drugs@FDA application ANDA077453

> The official Drugs@FDA dataset lists original submission 1 for ANDA 077453 with status AP dated 2008-01-24, and names oxytocin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda077453:v1`
- Evidence domain: Regulatory
- Date in source: 2008-01-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda077453/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#fda-drugs-anda077453-v1
- Content SHA-256: `bf40157d4f1b2670d2b662a366bcbf2363ab6080494f509cca9351e487e678ad`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA077453 ([`fda-drugs-anda077453-2008-01-24-cda96360b5c1`](#source-fda-drugs-anda077453-2008-01-24-cda96360b5c1))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 077453 with status AP dated 2008-01-24, and names oxytocin among the application record's active ingredients. ([`fda-drugs-anda077453-2008-01-24-cda96360b5c1`](#source-fda-drugs-anda077453-2008-01-24-cda96360b5c1))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 077453 with status AP dated 2008-01-24, and names oxytocin among the application record's active ingredients. ([`fda-drugs-anda077453-2008-01-24-cda96360b5c1`](#source-fda-drugs-anda077453-2008-01-24-cda96360b5c1))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda077453-2008-01-24-cda96360b5c1`](#source-fda-drugs-anda077453-2008-01-24-cda96360b5c1))

### Sources

<a id="source-fda-drugs-anda077453-2008-01-24-cda96360b5c1"></a>
- **Drugs@FDA application ANDA077453 · original submission status AP · 2008-01-24 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA077453%22&limit=1) (`fda-drugs-anda077453-2008-01-24-cda96360b5c1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA077453." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#fda-drugs-anda077453-v1 SHA-256: bf40157d4f1b2670d2b662a366bcbf2363ab6080494f509cca9351e487e678ad.

---

<a id="fda-drugs-anda091676-v1"></a>

## Drugs@FDA application ANDA091676

> The official Drugs@FDA dataset lists original submission 1 for ANDA 091676 with status AP dated 2018-07-13, and names oxytocin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda091676:v1`
- Evidence domain: Regulatory
- Date in source: 2018-07-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda091676/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#fda-drugs-anda091676-v1
- Content SHA-256: `276e926ca67ecfbda950628f22426b7b8dabb10ce82761cac470a11eb108826a`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA091676 ([`fda-drugs-anda091676-2018-07-13-e21f1f8e7302`](#source-fda-drugs-anda091676-2018-07-13-e21f1f8e7302))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 091676 with status AP dated 2018-07-13, and names oxytocin among the application record's active ingredients. ([`fda-drugs-anda091676-2018-07-13-e21f1f8e7302`](#source-fda-drugs-anda091676-2018-07-13-e21f1f8e7302))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 091676 with status AP dated 2018-07-13, and names oxytocin among the application record's active ingredients. ([`fda-drugs-anda091676-2018-07-13-e21f1f8e7302`](#source-fda-drugs-anda091676-2018-07-13-e21f1f8e7302))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda091676-2018-07-13-e21f1f8e7302`](#source-fda-drugs-anda091676-2018-07-13-e21f1f8e7302))

### Sources

<a id="source-fda-drugs-anda091676-2018-07-13-e21f1f8e7302"></a>
- **Drugs@FDA application ANDA091676 · original submission status AP · 2018-07-13 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA091676%22&limit=1) (`fda-drugs-anda091676-2018-07-13-e21f1f8e7302`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA091676." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#fda-drugs-anda091676-v1 SHA-256: 276e926ca67ecfbda950628f22426b7b8dabb10ce82761cac470a11eb108826a.

---

<a id="fda-drugs-anda200219-v1"></a>

## Drugs@FDA application ANDA200219

> The official Drugs@FDA dataset lists original submission 1 for ANDA 200219 with status AP dated 2013-02-13, and names oxytocin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda200219:v1`
- Evidence domain: Regulatory
- Date in source: 2013-02-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda200219/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#fda-drugs-anda200219-v1
- Content SHA-256: `84a6c44219edd8eee3c2c3324eea58f8e3811514c2fc853a495197f9c6f28a88`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA200219 ([`fda-drugs-anda200219-2013-02-13-39fd13735cd0`](#source-fda-drugs-anda200219-2013-02-13-39fd13735cd0))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 200219 with status AP dated 2013-02-13, and names oxytocin among the application record's active ingredients. ([`fda-drugs-anda200219-2013-02-13-39fd13735cd0`](#source-fda-drugs-anda200219-2013-02-13-39fd13735cd0))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 200219 with status AP dated 2013-02-13, and names oxytocin among the application record's active ingredients. ([`fda-drugs-anda200219-2013-02-13-39fd13735cd0`](#source-fda-drugs-anda200219-2013-02-13-39fd13735cd0))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda200219-2013-02-13-39fd13735cd0`](#source-fda-drugs-anda200219-2013-02-13-39fd13735cd0))

### Sources

<a id="source-fda-drugs-anda200219-2013-02-13-39fd13735cd0"></a>
- **Drugs@FDA application ANDA200219 · original submission status AP · 2013-02-13 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA200219%22&limit=1) (`fda-drugs-anda200219-2013-02-13-39fd13735cd0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA200219." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#fda-drugs-anda200219-v1 SHA-256: 84a6c44219edd8eee3c2c3324eea58f8e3811514c2fc853a495197f9c6f28a88.

---

<a id="fda-drugs-nda018243-v1"></a>

## Drugs@FDA application NDA018243

> The official Drugs@FDA dataset lists original submission 1 for NDA 018243 with status AP dated 1980-04-29, and names oxytocin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda018243:v1`
- Evidence domain: Regulatory
- Date in source: 1980-04-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda018243/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#fda-drugs-nda018243-v1
- Content SHA-256: `4405161f9ef95b5e0bd3c919c04be81f3ac3a602cdcfa2d2a60710000941bfe2`

### Claims and source pins

#### Headline

Drugs@FDA application NDA018243 ([`fda-drugs-nda018243-1980-04-29-685dcf5fd1e0`](#source-fda-drugs-nda018243-1980-04-29-685dcf5fd1e0))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 018243 with status AP dated 1980-04-29, and names oxytocin among the application record's active ingredients. ([`fda-drugs-nda018243-1980-04-29-685dcf5fd1e0`](#source-fda-drugs-nda018243-1980-04-29-685dcf5fd1e0))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 018243 with status AP dated 1980-04-29, and names oxytocin among the application record's active ingredients. ([`fda-drugs-nda018243-1980-04-29-685dcf5fd1e0`](#source-fda-drugs-nda018243-1980-04-29-685dcf5fd1e0))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda018243-1980-04-29-685dcf5fd1e0`](#source-fda-drugs-nda018243-1980-04-29-685dcf5fd1e0))

### Sources

<a id="source-fda-drugs-nda018243-1980-04-29-685dcf5fd1e0"></a>
- **Drugs@FDA application NDA018243 · original submission status AP · 1980-04-29 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA018243%22&limit=1) (`fda-drugs-nda018243-1980-04-29-685dcf5fd1e0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA018243." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#fda-drugs-nda018243-v1 SHA-256: 4405161f9ef95b5e0bd3c919c04be81f3ac3a602cdcfa2d2a60710000941bfe2.

---

<a id="fda-drugs-nda018245-v1"></a>

## Drugs@FDA application NDA018245

> The official Drugs@FDA dataset lists original submission 1 for NDA 018245 with status AP dated 1980-04-17, and names oxytocin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda018245:v1`
- Evidence domain: Regulatory
- Date in source: 1980-04-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda018245/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#fda-drugs-nda018245-v1
- Content SHA-256: `c9fe282ded020fd65ed9dba380b1bb1f9cbb4de4473119ac789d4499a1f940ac`

### Claims and source pins

#### Headline

Drugs@FDA application NDA018245 ([`fda-drugs-nda018245-1980-04-17-45919dc5a3a3`](#source-fda-drugs-nda018245-1980-04-17-45919dc5a3a3))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 018245 with status AP dated 1980-04-17, and names oxytocin among the application record's active ingredients. ([`fda-drugs-nda018245-1980-04-17-45919dc5a3a3`](#source-fda-drugs-nda018245-1980-04-17-45919dc5a3a3))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 018245 with status AP dated 1980-04-17, and names oxytocin among the application record's active ingredients. ([`fda-drugs-nda018245-1980-04-17-45919dc5a3a3`](#source-fda-drugs-nda018245-1980-04-17-45919dc5a3a3))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda018245-1980-04-17-45919dc5a3a3`](#source-fda-drugs-nda018245-1980-04-17-45919dc5a3a3))

### Sources

<a id="source-fda-drugs-nda018245-1980-04-17-45919dc5a3a3"></a>
- **Drugs@FDA application NDA018245 · original submission status AP · 1980-04-17 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA018245%22&limit=1) (`fda-drugs-nda018245-1980-04-17-45919dc5a3a3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA018245." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#fda-drugs-nda018245-v1 SHA-256: c9fe282ded020fd65ed9dba380b1bb1f9cbb4de4473119ac789d4499a1f940ac.

---

<a id="fda-drugs-nda018248-v1"></a>

## Drugs@FDA application NDA018248

> The official Drugs@FDA dataset lists original submission 1 for NDA 018248 with status AP dated 1980-07-09, and names oxytocin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda018248:v1`
- Evidence domain: Regulatory
- Date in source: 1980-07-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda018248/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#fda-drugs-nda018248-v1
- Content SHA-256: `868af57e0440bfd0fa5ae6f36fa0a0e3e7e71790789fa89002d9ece2430a4823`

### Claims and source pins

#### Headline

Drugs@FDA application NDA018248 ([`fda-drugs-nda018248-1980-07-09-5e3512cdbe14`](#source-fda-drugs-nda018248-1980-07-09-5e3512cdbe14))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 018248 with status AP dated 1980-07-09, and names oxytocin among the application record's active ingredients. ([`fda-drugs-nda018248-1980-07-09-5e3512cdbe14`](#source-fda-drugs-nda018248-1980-07-09-5e3512cdbe14))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 018248 with status AP dated 1980-07-09, and names oxytocin among the application record's active ingredients. ([`fda-drugs-nda018248-1980-07-09-5e3512cdbe14`](#source-fda-drugs-nda018248-1980-07-09-5e3512cdbe14))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda018248-1980-07-09-5e3512cdbe14`](#source-fda-drugs-nda018248-1980-07-09-5e3512cdbe14))

### Sources

<a id="source-fda-drugs-nda018248-1980-07-09-5e3512cdbe14"></a>
- **Drugs@FDA application NDA018248 · original submission status AP · 1980-07-09 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA018248%22&limit=1) (`fda-drugs-nda018248-1980-07-09-5e3512cdbe14`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA018248." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#fda-drugs-nda018248-v1 SHA-256: 868af57e0440bfd0fa5ae6f36fa0a0e3e7e71790789fa89002d9ece2430a4823.

---

<a id="fda-drugs-nda018261-v1"></a>

## Drugs@FDA application NDA018261

> The official Drugs@FDA dataset lists original submission 1 for NDA 018261 with status AP dated 1980-11-19, and names oxytocin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda018261:v1`
- Evidence domain: Regulatory
- Date in source: 1980-11-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda018261/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#fda-drugs-nda018261-v1
- Content SHA-256: `48fadf688aad4807b00001b10f3c4337a229dcbb8a4f8bb191d66f4431179baf`

### Claims and source pins

#### Headline

Drugs@FDA application NDA018261 ([`fda-drugs-nda018261-1980-11-19-8651cbb0db40`](#source-fda-drugs-nda018261-1980-11-19-8651cbb0db40))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 018261 with status AP dated 1980-11-19, and names oxytocin among the application record's active ingredients. ([`fda-drugs-nda018261-1980-11-19-8651cbb0db40`](#source-fda-drugs-nda018261-1980-11-19-8651cbb0db40))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 018261 with status AP dated 1980-11-19, and names oxytocin among the application record's active ingredients. ([`fda-drugs-nda018261-1980-11-19-8651cbb0db40`](#source-fda-drugs-nda018261-1980-11-19-8651cbb0db40))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda018261-1980-11-19-8651cbb0db40`](#source-fda-drugs-nda018261-1980-11-19-8651cbb0db40))

### Sources

<a id="source-fda-drugs-nda018261-1980-11-19-8651cbb0db40"></a>
- **Drugs@FDA application NDA018261 · original submission status AP · 1980-11-19 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA018261%22&limit=1) (`fda-drugs-nda018261-1980-11-19-8651cbb0db40`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA018261." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#fda-drugs-nda018261-v1 SHA-256: 48fadf688aad4807b00001b10f3c4337a229dcbb8a4f8bb191d66f4431179baf.

---

<a id="fda-drugs-nda019185-v1"></a>

## Drugs@FDA application NDA019185

> The official Drugs@FDA dataset lists original submission 1 for NDA 019185 with status AP dated 1985-03-29, and names oxytocin among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda019185:v1`
- Evidence domain: Regulatory
- Date in source: 1985-03-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda019185/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#fda-drugs-nda019185-v1
- Content SHA-256: `e9ac01f1a8e68ccb5371f93e8360348044916779f902d036314472e83c9f6739`

### Claims and source pins

#### Headline

Drugs@FDA application NDA019185 ([`fda-drugs-nda019185-1985-03-29-0273e5902bd4`](#source-fda-drugs-nda019185-1985-03-29-0273e5902bd4))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 019185 with status AP dated 1985-03-29, and names oxytocin among the application record's active ingredients. ([`fda-drugs-nda019185-1985-03-29-0273e5902bd4`](#source-fda-drugs-nda019185-1985-03-29-0273e5902bd4))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 019185 with status AP dated 1985-03-29, and names oxytocin among the application record's active ingredients. ([`fda-drugs-nda019185-1985-03-29-0273e5902bd4`](#source-fda-drugs-nda019185-1985-03-29-0273e5902bd4))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda019185-1985-03-29-0273e5902bd4`](#source-fda-drugs-nda019185-1985-03-29-0273e5902bd4))

### Sources

<a id="source-fda-drugs-nda019185-1985-03-29-0273e5902bd4"></a>
- **Drugs@FDA application NDA019185 · original submission status AP · 1985-03-29 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA019185%22&limit=1) (`fda-drugs-nda019185-1985-03-29-0273e5902bd4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA019185." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#fda-drugs-nda019185-v1 SHA-256: e9ac01f1a8e68ccb5371f93e8360348044916779f902d036314472e83c9f6739.

---

<a id="federal-register-00-18828-v1"></a>

## Federal Register rule 00-18828

> The Federal Register published rule 00-18828, attributed to FDA and its parent HHS department, on 2000-07-26. Its official title is “New Animal Drugs; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-00-18828:v1`
- Evidence domain: Regulatory
- Date in source: 2000-07-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-00-18828/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-00-18828-v1
- Content SHA-256: `f80395b6916657a4f9d58d8583746d4f837bbd5f5c7d8347f446e48e355846d0`

### Claims and source pins

#### Headline

Federal Register rule 00-18828 ([`federal-register-00-18828-7f74f264f8b6`](#source-federal-register-00-18828-7f74f264f8b6))

#### Summary

The Federal Register published rule 00-18828, attributed to FDA and its parent HHS department, on 2000-07-26. Its official title is “New Animal Drugs; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-00-18828-7f74f264f8b6`](#source-federal-register-00-18828-7f74f264f8b6))

#### Paragraph 1

The Federal Register published rule 00-18828, attributed to FDA and its parent HHS department, on 2000-07-26. Its official title is “New Animal Drugs; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-00-18828-7f74f264f8b6`](#source-federal-register-00-18828-7f74f264f8b6))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-00-18828-7f74f264f8b6`](#source-federal-register-00-18828-7f74f264f8b6))

### Sources

<a id="source-federal-register-00-18828-7f74f264f8b6"></a>
- **Federal Register rule 00-18828 · published 2000-07-26 · New Animal Drugs; Change of Sponsor** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2000-07-26/pdf/00-18828.pdf) (`federal-register-00-18828-7f74f264f8b6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register rule 00-18828." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-00-18828-v1 SHA-256: f80395b6916657a4f9d58d8583746d4f837bbd5f5c7d8347f446e48e355846d0.

---

<a id="federal-register-01-11070-v1"></a>

## Federal Register rule 01-11070

> The Federal Register published rule 01-11070, attributed to FDA and its parent HHS department, on 2001-05-03. Its official title is “Animal Drugs, Feeds, and Related Products; Tylosin Tartrate for Injection, etc.; Withdrawal of Approval of NADAs,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-01-11070:v1`
- Evidence domain: Regulatory
- Date in source: 2001-05-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-01-11070/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-01-11070-v1
- Content SHA-256: `e5a9a82928a4a4bf0c2eef8af5fc54c3ff783bef92041a0a46d88b94438a4465`

### Claims and source pins

#### Headline

Federal Register rule 01-11070 ([`federal-register-01-11070-1a7857ed1a76`](#source-federal-register-01-11070-1a7857ed1a76))

#### Summary

The Federal Register published rule 01-11070, attributed to FDA and its parent HHS department, on 2001-05-03. Its official title is “Animal Drugs, Feeds, and Related Products; Tylosin Tartrate for Injection, etc.; Withdrawal of Approval of NADAs,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-01-11070-1a7857ed1a76`](#source-federal-register-01-11070-1a7857ed1a76))

#### Paragraph 1

The Federal Register published rule 01-11070, attributed to FDA and its parent HHS department, on 2001-05-03. Its official title is “Animal Drugs, Feeds, and Related Products; Tylosin Tartrate for Injection, etc.; Withdrawal of Approval of NADAs,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-01-11070-1a7857ed1a76`](#source-federal-register-01-11070-1a7857ed1a76))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-01-11070-1a7857ed1a76`](#source-federal-register-01-11070-1a7857ed1a76))

### Sources

<a id="source-federal-register-01-11070-1a7857ed1a76"></a>
- **Federal Register rule 01-11070 · published 2001-05-03 · Animal Drugs, Feeds, and Related Products; Tylosin Tartrate for Injection, etc.; Withdrawal of Approval of NADAs** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2001-05-03/pdf/01-11070.pdf) (`federal-register-01-11070-1a7857ed1a76`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register rule 01-11070." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-01-11070-v1 SHA-256: e5a9a82928a4a4bf0c2eef8af5fc54c3ff783bef92041a0a46d88b94438a4465.

---

<a id="federal-register-01-11071-v1"></a>

## Federal Register notice 01-11071

> The Federal Register published notice 01-11071, attributed to FDA and its parent HHS department, on 2001-05-03. Its official title is “Elanco Animal Health, A Div. of Eli Lilly & Co. et al.; Withdrawal of Approval of NADAs,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-01-11071:v1`
- Evidence domain: Regulatory
- Date in source: 2001-05-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-01-11071/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-01-11071-v1
- Content SHA-256: `9d57188d82b5c84d743906540d0560e10141c1eb3c19214a9a92012ef0390d0d`

### Claims and source pins

#### Headline

Federal Register notice 01-11071 ([`federal-register-01-11071-393fc958f5b1`](#source-federal-register-01-11071-393fc958f5b1))

#### Summary

The Federal Register published notice 01-11071, attributed to FDA and its parent HHS department, on 2001-05-03. Its official title is “Elanco Animal Health, A Div. of Eli Lilly & Co. et al.; Withdrawal of Approval of NADAs,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-01-11071-393fc958f5b1`](#source-federal-register-01-11071-393fc958f5b1))

#### Paragraph 1

The Federal Register published notice 01-11071, attributed to FDA and its parent HHS department, on 2001-05-03. Its official title is “Elanco Animal Health, A Div. of Eli Lilly & Co. et al.; Withdrawal of Approval of NADAs,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-01-11071-393fc958f5b1`](#source-federal-register-01-11071-393fc958f5b1))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-01-11071-393fc958f5b1`](#source-federal-register-01-11071-393fc958f5b1))

### Sources

<a id="source-federal-register-01-11071-393fc958f5b1"></a>
- **Federal Register notice 01-11071 · published 2001-05-03 · Elanco Animal Health, A Div. of Eli Lilly & Co. et al.; Withdrawal of Approval of NADAs** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2001-05-03/pdf/01-11071.pdf) (`federal-register-01-11071-393fc958f5b1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 01-11071." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-01-11071-v1 SHA-256: 9d57188d82b5c84d743906540d0560e10141c1eb3c19214a9a92012ef0390d0d.

---

<a id="federal-register-01-11620-v1"></a>

## Federal Register notice 01-11620

> The Federal Register published notice 01-11620, attributed to FDA and its parent HHS department, on 2001-05-09. Its official title is “Purina Mills, Inc., et al.; Withdrawal of Approval of New Animal Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-01-11620:v1`
- Evidence domain: Regulatory
- Date in source: 2001-05-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-01-11620/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-01-11620-v1
- Content SHA-256: `82f0c4c71c177f7392cfde0aa29bd6bcf0332021c551494916b3542d67bde38c`

### Claims and source pins

#### Headline

Federal Register notice 01-11620 ([`federal-register-01-11620-e5a66516983a`](#source-federal-register-01-11620-e5a66516983a))

#### Summary

The Federal Register published notice 01-11620, attributed to FDA and its parent HHS department, on 2001-05-09. Its official title is “Purina Mills, Inc., et al.; Withdrawal of Approval of New Animal Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-01-11620-e5a66516983a`](#source-federal-register-01-11620-e5a66516983a))

#### Paragraph 1

The Federal Register published notice 01-11620, attributed to FDA and its parent HHS department, on 2001-05-09. Its official title is “Purina Mills, Inc., et al.; Withdrawal of Approval of New Animal Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-01-11620-e5a66516983a`](#source-federal-register-01-11620-e5a66516983a))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-01-11620-e5a66516983a`](#source-federal-register-01-11620-e5a66516983a))

### Sources

<a id="source-federal-register-01-11620-e5a66516983a"></a>
- **Federal Register notice 01-11620 · published 2001-05-09 · Purina Mills, Inc., et al.; Withdrawal of Approval of New Animal Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2001-05-09/pdf/01-11620.pdf) (`federal-register-01-11620-e5a66516983a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 01-11620." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-01-11620-v1 SHA-256: 82f0c4c71c177f7392cfde0aa29bd6bcf0332021c551494916b3542d67bde38c.

---

<a id="federal-register-01-11621-v1"></a>

## Federal Register rule 01-11621

> The Federal Register published rule 01-11621, attributed to FDA and its parent HHS department, on 2001-05-09. Its official title is “Animal Drugs, Feeds, and Related Products; Trichlorfon, etc.; Withdrawal of Approval of NADAs,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-01-11621:v1`
- Evidence domain: Regulatory
- Date in source: 2001-05-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-01-11621/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-01-11621-v1
- Content SHA-256: `7f40e4cef209065d7bb297b169a66d5ed1aa0cc563c9de72f132fa25878d3700`

### Claims and source pins

#### Headline

Federal Register rule 01-11621 ([`federal-register-01-11621-53d9f1e249c3`](#source-federal-register-01-11621-53d9f1e249c3))

#### Summary

The Federal Register published rule 01-11621, attributed to FDA and its parent HHS department, on 2001-05-09. Its official title is “Animal Drugs, Feeds, and Related Products; Trichlorfon, etc.; Withdrawal of Approval of NADAs,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-01-11621-53d9f1e249c3`](#source-federal-register-01-11621-53d9f1e249c3))

#### Paragraph 1

The Federal Register published rule 01-11621, attributed to FDA and its parent HHS department, on 2001-05-09. Its official title is “Animal Drugs, Feeds, and Related Products; Trichlorfon, etc.; Withdrawal of Approval of NADAs,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-01-11621-53d9f1e249c3`](#source-federal-register-01-11621-53d9f1e249c3))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-01-11621-53d9f1e249c3`](#source-federal-register-01-11621-53d9f1e249c3))

### Sources

<a id="source-federal-register-01-11621-53d9f1e249c3"></a>
- **Federal Register rule 01-11621 · published 2001-05-09 · Animal Drugs, Feeds, and Related Products; Trichlorfon, etc.; Withdrawal of Approval of NADAs** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2001-05-09/pdf/01-11621.pdf) (`federal-register-01-11621-53d9f1e249c3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register rule 01-11621." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-01-11621-v1 SHA-256: 7f40e4cef209065d7bb297b169a66d5ed1aa0cc563c9de72f132fa25878d3700.

---

<a id="federal-register-03-15618-v1"></a>

## Federal Register rule 03-15618

> The Federal Register published rule 03-15618, attributed to FDA and its parent HHS department, on 2003-06-20. Its official title is “Dosage Form New Animal Drugs; Change of Sponsor; Technical Amendment,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-03-15618:v1`
- Evidence domain: Regulatory
- Date in source: 2003-06-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-03-15618/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-03-15618-v1
- Content SHA-256: `16ac731c7094413a9f0a29d764a6d954cd1220eef22ff685400cf70e92372aa1`

### Claims and source pins

#### Headline

Federal Register rule 03-15618 ([`federal-register-03-15618-759fb306e851`](#source-federal-register-03-15618-759fb306e851))

#### Summary

The Federal Register published rule 03-15618, attributed to FDA and its parent HHS department, on 2003-06-20. Its official title is “Dosage Form New Animal Drugs; Change of Sponsor; Technical Amendment,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-03-15618-759fb306e851`](#source-federal-register-03-15618-759fb306e851))

#### Paragraph 1

The Federal Register published rule 03-15618, attributed to FDA and its parent HHS department, on 2003-06-20. Its official title is “Dosage Form New Animal Drugs; Change of Sponsor; Technical Amendment,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-03-15618-759fb306e851`](#source-federal-register-03-15618-759fb306e851))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-03-15618-759fb306e851`](#source-federal-register-03-15618-759fb306e851))

### Sources

<a id="source-federal-register-03-15618-759fb306e851"></a>
- **Federal Register rule 03-15618 · published 2003-06-20 · Dosage Form New Animal Drugs; Change of Sponsor; Technical Amendment** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2003-06-20/pdf/03-15618.pdf) (`federal-register-03-15618-759fb306e851`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register rule 03-15618." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-03-15618-v1 SHA-256: 16ac731c7094413a9f0a29d764a6d954cd1220eef22ff685400cf70e92372aa1.

---

<a id="federal-register-04-15570-v1"></a>

## Federal Register notice 04-15570

> The Federal Register published notice 04-15570, attributed to FDA and its parent HHS department, on 2004-07-09. Its official title is “Notice of Approval of Abbreviated New Animal Drug Application; Oxytocin Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-04-15570:v1`
- Evidence domain: Regulatory
- Date in source: 2004-07-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-04-15570/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-04-15570-v1
- Content SHA-256: `9b937a47a655a114abd7e69c75b12101f8cbb20bd24b608d882dfeab1ee743ef`

### Claims and source pins

#### Headline

Federal Register notice 04-15570 ([`federal-register-04-15570-2a4dcf7c68c0`](#source-federal-register-04-15570-2a4dcf7c68c0))

#### Summary

The Federal Register published notice 04-15570, attributed to FDA and its parent HHS department, on 2004-07-09. Its official title is “Notice of Approval of Abbreviated New Animal Drug Application; Oxytocin Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-04-15570-2a4dcf7c68c0`](#source-federal-register-04-15570-2a4dcf7c68c0))

#### Paragraph 1

The Federal Register published notice 04-15570, attributed to FDA and its parent HHS department, on 2004-07-09. Its official title is “Notice of Approval of Abbreviated New Animal Drug Application; Oxytocin Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-04-15570-2a4dcf7c68c0`](#source-federal-register-04-15570-2a4dcf7c68c0))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-04-15570-2a4dcf7c68c0`](#source-federal-register-04-15570-2a4dcf7c68c0))

### Sources

<a id="source-federal-register-04-15570-2a4dcf7c68c0"></a>
- **Federal Register notice 04-15570 · published 2004-07-09 · Notice of Approval of Abbreviated New Animal Drug Application; Oxytocin Injection** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2004-07-09/pdf/04-15570.pdf) (`federal-register-04-15570-2a4dcf7c68c0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 04-15570." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-04-15570-v1 SHA-256: 9b937a47a655a114abd7e69c75b12101f8cbb20bd24b608d882dfeab1ee743ef.

---

<a id="federal-register-2012-22195-v1"></a>

## Federal Register notice 2012-22195

> The Federal Register published notice 2012-22195, attributed to FDA and its parent HHS department, on 2012-09-10. Its official title is “Withdrawal of Approval of New Animal Drug Applications; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-2012-22195:v1`
- Evidence domain: Regulatory
- Date in source: 2012-09-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2012-22195/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-2012-22195-v1
- Content SHA-256: `0b44f894f7575146b8ffcc551466f7e27d2695da2be94a018ca3b94cc10f01e0`

### Claims and source pins

#### Headline

Federal Register notice 2012-22195 ([`federal-register-2012-22195-2875fb533825`](#source-federal-register-2012-22195-2875fb533825))

#### Summary

The Federal Register published notice 2012-22195, attributed to FDA and its parent HHS department, on 2012-09-10. Its official title is “Withdrawal of Approval of New Animal Drug Applications; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-2012-22195-2875fb533825`](#source-federal-register-2012-22195-2875fb533825))

#### Paragraph 1

The Federal Register published notice 2012-22195, attributed to FDA and its parent HHS department, on 2012-09-10. Its official title is “Withdrawal of Approval of New Animal Drug Applications; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-2012-22195-2875fb533825`](#source-federal-register-2012-22195-2875fb533825))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2012-22195-2875fb533825`](#source-federal-register-2012-22195-2875fb533825))

### Sources

<a id="source-federal-register-2012-22195-2875fb533825"></a>
- **Federal Register notice 2012-22195 · published 2012-09-10 · Withdrawal of Approval of New Animal Drug Applications; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2012-09-10/pdf/2012-22195.pdf) (`federal-register-2012-22195-2875fb533825`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2012-22195." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-2012-22195-v1 SHA-256: 0b44f894f7575146b8ffcc551466f7e27d2695da2be94a018ca3b94cc10f01e0.

---

<a id="federal-register-2012-22196-v1"></a>

## Federal Register rule 2012-22196

> The Federal Register published rule 2012-22196, attributed to FDA and its parent HHS department, on 2012-09-10. Its official title is “New Animal Drugs; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-2012-22196:v1`
- Evidence domain: Regulatory
- Date in source: 2012-09-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2012-22196/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-2012-22196-v1
- Content SHA-256: `71d090bcec10fc0d9f990c004680eca0b8462f5ef3fc5666b9107d39b375188c`

### Claims and source pins

#### Headline

Federal Register rule 2012-22196 ([`federal-register-2012-22196-55e647f7d87f`](#source-federal-register-2012-22196-55e647f7d87f))

#### Summary

The Federal Register published rule 2012-22196, attributed to FDA and its parent HHS department, on 2012-09-10. Its official title is “New Animal Drugs; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-2012-22196-55e647f7d87f`](#source-federal-register-2012-22196-55e647f7d87f))

#### Paragraph 1

The Federal Register published rule 2012-22196, attributed to FDA and its parent HHS department, on 2012-09-10. Its official title is “New Animal Drugs; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-2012-22196-55e647f7d87f`](#source-federal-register-2012-22196-55e647f7d87f))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2012-22196-55e647f7d87f`](#source-federal-register-2012-22196-55e647f7d87f))

### Sources

<a id="source-federal-register-2012-22196-55e647f7d87f"></a>
- **Federal Register rule 2012-22196 · published 2012-09-10 · New Animal Drugs; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2012-09-10/pdf/2012-22196.pdf) (`federal-register-2012-22196-55e647f7d87f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register rule 2012-22196." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-2012-22196-v1 SHA-256: 71d090bcec10fc0d9f990c004680eca0b8462f5ef3fc5666b9107d39b375188c.

---

<a id="federal-register-2013-06126-v1"></a>

## Federal Register rule 2013-06126

> The Federal Register published rule 2013-06126, attributed to FDA and its parent HHS department, on 2013-03-22. Its official title is “New Animal Drugs; Changes of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-2013-06126:v1`
- Evidence domain: Regulatory
- Date in source: 2013-03-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2013-06126/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-2013-06126-v1
- Content SHA-256: `6e234f09691178fa06ce02dd2184dd90cbc5b4425ca70388424f902a971118c6`

### Claims and source pins

#### Headline

Federal Register rule 2013-06126 ([`federal-register-2013-06126-ef92e1cf9004`](#source-federal-register-2013-06126-ef92e1cf9004))

#### Summary

The Federal Register published rule 2013-06126, attributed to FDA and its parent HHS department, on 2013-03-22. Its official title is “New Animal Drugs; Changes of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-2013-06126-ef92e1cf9004`](#source-federal-register-2013-06126-ef92e1cf9004))

#### Paragraph 1

The Federal Register published rule 2013-06126, attributed to FDA and its parent HHS department, on 2013-03-22. Its official title is “New Animal Drugs; Changes of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-2013-06126-ef92e1cf9004`](#source-federal-register-2013-06126-ef92e1cf9004))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2013-06126-ef92e1cf9004`](#source-federal-register-2013-06126-ef92e1cf9004))

### Sources

<a id="source-federal-register-2013-06126-ef92e1cf9004"></a>
- **Federal Register rule 2013-06126 · published 2013-03-22 · New Animal Drugs; Changes of Sponsor** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2013-03-22/pdf/2013-06126.pdf) (`federal-register-2013-06126-ef92e1cf9004`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register rule 2013-06126." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-2013-06126-v1 SHA-256: 6e234f09691178fa06ce02dd2184dd90cbc5b4425ca70388424f902a971118c6.

---

<a id="federal-register-2013-07542-v1"></a>

## Federal Register rule 2013-07542

> The Federal Register published rule 2013-07542, attributed to FDA and its parent HHS department, on 2013-04-09. Its official title is “New Animal Drugs; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-2013-07542:v1`
- Evidence domain: Regulatory
- Date in source: 2013-04-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2013-07542/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-2013-07542-v1
- Content SHA-256: `1e02430293a6121c6491deac6a2c99b0c9a87b1e4eb00545aedb4c0fe1a5bc35`

### Claims and source pins

#### Headline

Federal Register rule 2013-07542 ([`federal-register-2013-07542-425bc0541003`](#source-federal-register-2013-07542-425bc0541003))

#### Summary

The Federal Register published rule 2013-07542, attributed to FDA and its parent HHS department, on 2013-04-09. Its official title is “New Animal Drugs; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-2013-07542-425bc0541003`](#source-federal-register-2013-07542-425bc0541003))

#### Paragraph 1

The Federal Register published rule 2013-07542, attributed to FDA and its parent HHS department, on 2013-04-09. Its official title is “New Animal Drugs; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-2013-07542-425bc0541003`](#source-federal-register-2013-07542-425bc0541003))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2013-07542-425bc0541003`](#source-federal-register-2013-07542-425bc0541003))

### Sources

<a id="source-federal-register-2013-07542-425bc0541003"></a>
- **Federal Register rule 2013-07542 · published 2013-04-09 · New Animal Drugs; Change of Sponsor** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2013-04-09/pdf/2013-07542.pdf) (`federal-register-2013-07542-425bc0541003`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register rule 2013-07542." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-2013-07542-v1 SHA-256: 1e02430293a6121c6491deac6a2c99b0c9a87b1e4eb00545aedb4c0fe1a5bc35.

---

<a id="federal-register-2014-06131-v1"></a>

## Federal Register rule 2014-06131

> The Federal Register published rule 2014-06131, attributed to FDA and its parent HHS department, on 2014-03-25. Its official title is “Implantation or Injectable Dosage Form New Animal Drugs; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-2014-06131:v1`
- Evidence domain: Regulatory
- Date in source: 2014-03-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2014-06131/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-2014-06131-v1
- Content SHA-256: `be765cfb0b32ba30dcea2da7d3dd0bdf3e141e44755cc77f102047f0263a2975`

### Claims and source pins

#### Headline

Federal Register rule 2014-06131 ([`federal-register-2014-06131-eba5153f5024`](#source-federal-register-2014-06131-eba5153f5024))

#### Summary

The Federal Register published rule 2014-06131, attributed to FDA and its parent HHS department, on 2014-03-25. Its official title is “Implantation or Injectable Dosage Form New Animal Drugs; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-2014-06131-eba5153f5024`](#source-federal-register-2014-06131-eba5153f5024))

#### Paragraph 1

The Federal Register published rule 2014-06131, attributed to FDA and its parent HHS department, on 2014-03-25. Its official title is “Implantation or Injectable Dosage Form New Animal Drugs; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-2014-06131-eba5153f5024`](#source-federal-register-2014-06131-eba5153f5024))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2014-06131-eba5153f5024`](#source-federal-register-2014-06131-eba5153f5024))

### Sources

<a id="source-federal-register-2014-06131-eba5153f5024"></a>
- **Federal Register rule 2014-06131 · published 2014-03-25 · Implantation or Injectable Dosage Form New Animal Drugs; Change of Sponsor** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2014-03-25/pdf/2014-06131.pdf) (`federal-register-2014-06131-eba5153f5024`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register rule 2014-06131." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-2014-06131-v1 SHA-256: be765cfb0b32ba30dcea2da7d3dd0bdf3e141e44755cc77f102047f0263a2975.

---

<a id="federal-register-2015-09299-v1"></a>

## Federal Register notice 2015-09299

> The Federal Register published notice 2015-09299, attributed to FDA and its parent HHS department, on 2015-04-22. Its official title is “Determination That OXYTOCIN in 5% Dextrose Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-2015-09299:v1`
- Evidence domain: Regulatory
- Date in source: 2015-04-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2015-09299/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-2015-09299-v1
- Content SHA-256: `dcd39df9914d72e9c3ba158576613584bcad8f046711e5d346e720f7b769176b`

### Claims and source pins

#### Headline

Federal Register notice 2015-09299 ([`federal-register-2015-09299-a23910f46136`](#source-federal-register-2015-09299-a23910f46136))

#### Summary

The Federal Register published notice 2015-09299, attributed to FDA and its parent HHS department, on 2015-04-22. Its official title is “Determination That OXYTOCIN in 5% Dextrose Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-2015-09299-a23910f46136`](#source-federal-register-2015-09299-a23910f46136))

#### Paragraph 1

The Federal Register published notice 2015-09299, attributed to FDA and its parent HHS department, on 2015-04-22. Its official title is “Determination That OXYTOCIN in 5% Dextrose Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-2015-09299-a23910f46136`](#source-federal-register-2015-09299-a23910f46136))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2015-09299-a23910f46136`](#source-federal-register-2015-09299-a23910f46136))

### Sources

<a id="source-federal-register-2015-09299-a23910f46136"></a>
- **Federal Register notice 2015-09299 · published 2015-04-22 · Determination That OXYTOCIN in 5% Dextrose Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2015-04-22/pdf/2015-09299.pdf) (`federal-register-2015-09299-a23910f46136`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2015-09299." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-2015-09299-v1 SHA-256: dcd39df9914d72e9c3ba158576613584bcad8f046711e5d346e720f7b769176b.

---

<a id="federal-register-2016-13517-v1"></a>

## Federal Register rule 2016-13517

> The Federal Register published rule 2016-13517, attributed to FDA and its parent HHS department, on 2016-06-08. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-2016-13517:v1`
- Evidence domain: Regulatory
- Date in source: 2016-06-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2016-13517/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-2016-13517-v1
- Content SHA-256: `4b5767b661fbb37f7c69e37458fc6d7113c2b9f4c82f2abd7b03e28ca92b94ed`

### Claims and source pins

#### Headline

Federal Register rule 2016-13517 ([`federal-register-2016-13517-d354460f5776`](#source-federal-register-2016-13517-d354460f5776))

#### Summary

The Federal Register published rule 2016-13517, attributed to FDA and its parent HHS department, on 2016-06-08. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-2016-13517-d354460f5776`](#source-federal-register-2016-13517-d354460f5776))

#### Paragraph 1

The Federal Register published rule 2016-13517, attributed to FDA and its parent HHS department, on 2016-06-08. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-2016-13517-d354460f5776`](#source-federal-register-2016-13517-d354460f5776))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2016-13517-d354460f5776`](#source-federal-register-2016-13517-d354460f5776))

### Sources

<a id="source-federal-register-2016-13517-d354460f5776"></a>
- **Federal Register rule 2016-13517 · published 2016-06-08 · New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2016-06-08/pdf/2016-13517.pdf) (`federal-register-2016-13517-d354460f5776`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register rule 2016-13517." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-2016-13517-v1 SHA-256: 4b5767b661fbb37f7c69e37458fc6d7113c2b9f4c82f2abd7b03e28ca92b94ed.

---

<a id="federal-register-2018-06358-v1"></a>

## Federal Register rule 2018-06358

> The Federal Register published rule 2018-06358, attributed to FDA and its parent HHS department, on 2018-03-30. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship; Change of a Sponsor's Name and Address,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-2018-06358:v1`
- Evidence domain: Regulatory
- Date in source: 2018-03-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2018-06358/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-2018-06358-v1
- Content SHA-256: `d05fc26198d6f69cb27399683e3b89b0abb52e0af51b1a9c71d38ee5aeb5287c`

### Claims and source pins

#### Headline

Federal Register rule 2018-06358 ([`federal-register-2018-06358-7a495cca5c4e`](#source-federal-register-2018-06358-7a495cca5c4e))

#### Summary

The Federal Register published rule 2018-06358, attributed to FDA and its parent HHS department, on 2018-03-30. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship; Change of a Sponsor's Name and Address,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-2018-06358-7a495cca5c4e`](#source-federal-register-2018-06358-7a495cca5c4e))

#### Paragraph 1

The Federal Register published rule 2018-06358, attributed to FDA and its parent HHS department, on 2018-03-30. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship; Change of a Sponsor's Name and Address,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-2018-06358-7a495cca5c4e`](#source-federal-register-2018-06358-7a495cca5c4e))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2018-06358-7a495cca5c4e`](#source-federal-register-2018-06358-7a495cca5c4e))

### Sources

<a id="source-federal-register-2018-06358-7a495cca5c4e"></a>
- **Federal Register rule 2018-06358 · published 2018-03-30 · New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship; Change of a Sponsor's Name and Address** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2018-03-30/pdf/2018-06358.pdf) (`federal-register-2018-06358-7a495cca5c4e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register rule 2018-06358." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-2018-06358-v1 SHA-256: d05fc26198d6f69cb27399683e3b89b0abb52e0af51b1a9c71d38ee5aeb5287c.

---

<a id="federal-register-2019-04226-v1"></a>

## Federal Register rule 2019-04226

> The Federal Register published rule 2019-04226, attributed to FDA and its parent HHS department, on 2019-03-13. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-2019-04226:v1`
- Evidence domain: Regulatory
- Date in source: 2019-03-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2019-04226/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-2019-04226-v1
- Content SHA-256: `f16a069f5bea13c4d10bbf843dc6d702b5fe12556246b92c5d4bc64def5ff147`

### Claims and source pins

#### Headline

Federal Register rule 2019-04226 ([`federal-register-2019-04226-7f21456b7a21`](#source-federal-register-2019-04226-7f21456b7a21))

#### Summary

The Federal Register published rule 2019-04226, attributed to FDA and its parent HHS department, on 2019-03-13. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-2019-04226-7f21456b7a21`](#source-federal-register-2019-04226-7f21456b7a21))

#### Paragraph 1

The Federal Register published rule 2019-04226, attributed to FDA and its parent HHS department, on 2019-03-13. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-2019-04226-7f21456b7a21`](#source-federal-register-2019-04226-7f21456b7a21))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2019-04226-7f21456b7a21`](#source-federal-register-2019-04226-7f21456b7a21))

### Sources

<a id="source-federal-register-2019-04226-7f21456b7a21"></a>
- **Federal Register rule 2019-04226 · published 2019-03-13 · New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2019-03-13/pdf/2019-04226.pdf) (`federal-register-2019-04226-7f21456b7a21`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register rule 2019-04226." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-2019-04226-v1 SHA-256: f16a069f5bea13c4d10bbf843dc6d702b5fe12556246b92c5d4bc64def5ff147.

---

<a id="federal-register-95-15241-v1"></a>

## Federal Register rule 95-15241

> The Federal Register published rule 95-15241, attributed to FDA and its parent HHS department, on 1995-06-22. Its official title is “New Animal Drugs; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-95-15241:v1`
- Evidence domain: Regulatory
- Date in source: 1995-06-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-95-15241/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-95-15241-v1
- Content SHA-256: `c5b36448edbceb8fb45dc994d6370b0943bf6cd7165313101db4059d3944de21`

### Claims and source pins

#### Headline

Federal Register rule 95-15241 ([`federal-register-95-15241-54a39c47ed41`](#source-federal-register-95-15241-54a39c47ed41))

#### Summary

The Federal Register published rule 95-15241, attributed to FDA and its parent HHS department, on 1995-06-22. Its official title is “New Animal Drugs; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-95-15241-54a39c47ed41`](#source-federal-register-95-15241-54a39c47ed41))

#### Paragraph 1

The Federal Register published rule 95-15241, attributed to FDA and its parent HHS department, on 1995-06-22. Its official title is “New Animal Drugs; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-95-15241-54a39c47ed41`](#source-federal-register-95-15241-54a39c47ed41))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-95-15241-54a39c47ed41`](#source-federal-register-95-15241-54a39c47ed41))

### Sources

<a id="source-federal-register-95-15241-54a39c47ed41"></a>
- **Federal Register rule 95-15241 · published 1995-06-22 · New Animal Drugs; Change of Sponsor** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-1995-06-22/pdf/95-15241.pdf) (`federal-register-95-15241-54a39c47ed41`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register rule 95-15241." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-95-15241-v1 SHA-256: c5b36448edbceb8fb45dc994d6370b0943bf6cd7165313101db4059d3944de21.

---

<a id="federal-register-97-16967-v1"></a>

## Federal Register rule 97-16967

> The Federal Register published rule 97-16967, attributed to FDA and its parent HHS department, on 1997-06-30. Its official title is “Animal Drugs, Feeds, and Related Products; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-97-16967:v1`
- Evidence domain: Regulatory
- Date in source: 1997-06-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-97-16967/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-97-16967-v1
- Content SHA-256: `27f3baf69d36ae2e4d3c3336885069b9ef9f6adafaf4359d89e5e7faccd2f1b8`

### Claims and source pins

#### Headline

Federal Register rule 97-16967 ([`federal-register-97-16967-a7a74021aae7`](#source-federal-register-97-16967-a7a74021aae7))

#### Summary

The Federal Register published rule 97-16967, attributed to FDA and its parent HHS department, on 1997-06-30. Its official title is “Animal Drugs, Feeds, and Related Products; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-97-16967-a7a74021aae7`](#source-federal-register-97-16967-a7a74021aae7))

#### Paragraph 1

The Federal Register published rule 97-16967, attributed to FDA and its parent HHS department, on 1997-06-30. Its official title is “Animal Drugs, Feeds, and Related Products; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-97-16967-a7a74021aae7`](#source-federal-register-97-16967-a7a74021aae7))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-97-16967-a7a74021aae7`](#source-federal-register-97-16967-a7a74021aae7))

### Sources

<a id="source-federal-register-97-16967-a7a74021aae7"></a>
- **Federal Register rule 97-16967 · published 1997-06-30 · Animal Drugs, Feeds, and Related Products; Change of Sponsor** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-1997-06-30/pdf/97-16967.pdf) (`federal-register-97-16967-a7a74021aae7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register rule 97-16967." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-97-16967-v1 SHA-256: 27f3baf69d36ae2e4d3c3336885069b9ef9f6adafaf4359d89e5e7faccd2f1b8.

---

<a id="federal-register-97-19065-v1"></a>

## Federal Register notice 97-19065

> The Federal Register published notice 97-19065, attributed to FDA and its parent HHS department, on 1997-07-21. Its official title is “Babineaux's Veterinary Products, Inc., et al.; Withdrawal of Approval of NADA's,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-97-19065:v1`
- Evidence domain: Regulatory
- Date in source: 1997-07-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-97-19065/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-97-19065-v1
- Content SHA-256: `75d13f5f979de86542201e53d6de7f5b3f85d9ce97d56a5de5115d58cabfb49c`

### Claims and source pins

#### Headline

Federal Register notice 97-19065 ([`federal-register-97-19065-f0e7eb1816d6`](#source-federal-register-97-19065-f0e7eb1816d6))

#### Summary

The Federal Register published notice 97-19065, attributed to FDA and its parent HHS department, on 1997-07-21. Its official title is “Babineaux's Veterinary Products, Inc., et al.; Withdrawal of Approval of NADA's,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-97-19065-f0e7eb1816d6`](#source-federal-register-97-19065-f0e7eb1816d6))

#### Paragraph 1

The Federal Register published notice 97-19065, attributed to FDA and its parent HHS department, on 1997-07-21. Its official title is “Babineaux's Veterinary Products, Inc., et al.; Withdrawal of Approval of NADA's,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-97-19065-f0e7eb1816d6`](#source-federal-register-97-19065-f0e7eb1816d6))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-97-19065-f0e7eb1816d6`](#source-federal-register-97-19065-f0e7eb1816d6))

### Sources

<a id="source-federal-register-97-19065-f0e7eb1816d6"></a>
- **Federal Register notice 97-19065 · published 1997-07-21 · Babineaux's Veterinary Products, Inc., et al.; Withdrawal of Approval of NADA's** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-1997-07-21/pdf/97-19065.pdf) (`federal-register-97-19065-f0e7eb1816d6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 97-19065." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-97-19065-v1 SHA-256: 75d13f5f979de86542201e53d6de7f5b3f85d9ce97d56a5de5115d58cabfb49c.

---

<a id="federal-register-97-19066-v1"></a>

## Federal Register rule 97-19066

> The Federal Register published rule 97-19066, attributed to FDA and its parent HHS department, on 1997-07-21. Its official title is “Animal Drugs, Feeds, and Related Products,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-97-19066:v1`
- Evidence domain: Regulatory
- Date in source: 1997-07-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-97-19066/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-97-19066-v1
- Content SHA-256: `48532dbe22990172d03f7e52aa1a5f09f09369e065f986b9bdb522c13abeb773`

### Claims and source pins

#### Headline

Federal Register rule 97-19066 ([`federal-register-97-19066-74941dfca64c`](#source-federal-register-97-19066-74941dfca64c))

#### Summary

The Federal Register published rule 97-19066, attributed to FDA and its parent HHS department, on 1997-07-21. Its official title is “Animal Drugs, Feeds, and Related Products,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-97-19066-74941dfca64c`](#source-federal-register-97-19066-74941dfca64c))

#### Paragraph 1

The Federal Register published rule 97-19066, attributed to FDA and its parent HHS department, on 1997-07-21. Its official title is “Animal Drugs, Feeds, and Related Products,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-97-19066-74941dfca64c`](#source-federal-register-97-19066-74941dfca64c))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-97-19066-74941dfca64c`](#source-federal-register-97-19066-74941dfca64c))

### Sources

<a id="source-federal-register-97-19066-74941dfca64c"></a>
- **Federal Register rule 97-19066 · published 1997-07-21 · Animal Drugs, Feeds, and Related Products** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-1997-07-21/pdf/97-19066.pdf) (`federal-register-97-19066-74941dfca64c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register rule 97-19066." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-97-19066-v1 SHA-256: 48532dbe22990172d03f7e52aa1a5f09f09369e065f986b9bdb522c13abeb773.

---

<a id="federal-register-97-20871-v1"></a>

## Federal Register notice 97-20871

> The Federal Register published notice 97-20871, attributed to FDA and its parent HHS department, on 1997-08-07. Its official title is “Sterling Drug, Inc., et al.; Withdrawal of Approval of 28 New Drug Applications, 9 Abbreviated Antibiotic Applications, and 46 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

- Evidence object: `story:federal-register-97-20871:v1`
- Evidence domain: Regulatory
- Date in source: 1997-08-07
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-97-20871/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-97-20871-v1
- Content SHA-256: `d1d610c5db6d7ebc0933057a21ac58b64c09de219ffa6b291b7165f61ac80ae7`

### Claims and source pins

#### Headline

Federal Register notice 97-20871 ([`federal-register-97-20871-b0ca046a4119`](#source-federal-register-97-20871-b0ca046a4119))

#### Summary

The Federal Register published notice 97-20871, attributed to FDA and its parent HHS department, on 1997-08-07. Its official title is “Sterling Drug, Inc., et al.; Withdrawal of Approval of 28 New Drug Applications, 9 Abbreviated Antibiotic Applications, and 46 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-97-20871-b0ca046a4119`](#source-federal-register-97-20871-b0ca046a4119))

#### Paragraph 1

The Federal Register published notice 97-20871, attributed to FDA and its parent HHS department, on 1997-08-07. Its official title is “Sterling Drug, Inc., et al.; Withdrawal of Approval of 28 New Drug Applications, 9 Abbreviated Antibiotic Applications, and 46 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin. ([`federal-register-97-20871-b0ca046a4119`](#source-federal-register-97-20871-b0ca046a4119))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-97-20871-b0ca046a4119`](#source-federal-register-97-20871-b0ca046a4119))

### Sources

<a id="source-federal-register-97-20871-b0ca046a4119"></a>
- **Federal Register notice 97-20871 · published 1997-08-07 · Sterling Drug, Inc., et al.; Withdrawal of Approval of 28 New Drug Applications, 9 Abbreviated Antibiotic Applications, and 46 Abbreviated New Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-1997-08-07/pdf/97-20871.pdf) (`federal-register-97-20871-b0ca046a4119`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 97-20871." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-97-20871-v1 SHA-256: d1d610c5db6d7ebc0933057a21ac58b64c09de219ffa6b291b7165f61ac80ae7.

---

<a id="federal-register-e9-11628-v1"></a>

## Federal Register notice E9-11628

> The Federal Register published notice E9-11628, attributed to FDA and its parent HHS department, on 2009-05-19. Its official title is “Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin and Sermorelin.

- Evidence object: `story:federal-register-e9-11628:v1`
- Evidence domain: Regulatory
- Date in source: 2009-05-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-e9-11628/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-e9-11628-v1
- Content SHA-256: `3a326979315ed1676901e4400de5fb9785cde825ff76654663f8c8c0fb58904c`

### Claims and source pins

#### Headline

Federal Register notice E9-11628 ([`federal-register-e9-11628-5aa22ad16734`](#source-federal-register-e9-11628-5aa22ad16734))

#### Summary

The Federal Register published notice E9-11628, attributed to FDA and its parent HHS department, on 2009-05-19. Its official title is “Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin and Sermorelin. ([`federal-register-e9-11628-5aa22ad16734`](#source-federal-register-e9-11628-5aa22ad16734))

#### Paragraph 1

The Federal Register published notice E9-11628, attributed to FDA and its parent HHS department, on 2009-05-19. Its official title is “Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin and Sermorelin. ([`federal-register-e9-11628-5aa22ad16734`](#source-federal-register-e9-11628-5aa22ad16734))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-e9-11628-5aa22ad16734`](#source-federal-register-e9-11628-5aa22ad16734))

### Sources

<a id="source-federal-register-e9-11628-5aa22ad16734"></a>
- **Federal Register notice E9-11628 · published 2009-05-19 · Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2009-05-19/pdf/E9-11628.pdf) (`federal-register-e9-11628-5aa22ad16734`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice E9-11628." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#federal-register-e9-11628-v1 SHA-256: 3a326979315ed1676901e4400de5fb9785cde825ff76654663f8c8c0fb58904c.

---

<a id="pubmed-pmid-41389446-oxytocin-v1"></a>

## The active monitoring of oxytocin research evidence (AMORE) platform.

> PubMed lists PMID 41389446 in Psychoneuroendocrinology as Journal Article, Systematic Review, with publication-date metadata of 2025-12-05 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41389446-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41389446-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41389446-oxytocin-v1
- Content SHA-256: `9b8b0ee974d69f10561f788654c825fa9508c533b4ead56674084dff83bdc548`

### Claims and source pins

#### Headline

The active monitoring of oxytocin research evidence (AMORE) platform. ([`pubmed-observation-pmid-41389446-2026-01-27-7275701b421f`](#source-pubmed-observation-pmid-41389446-2026-01-27-7275701b421f))

#### Summary

PubMed lists PMID 41389446 in Psychoneuroendocrinology as Journal Article, Systematic Review, with publication-date metadata of 2025-12-05 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41389446-2026-01-27-7275701b421f`](#source-pubmed-observation-pmid-41389446-2026-01-27-7275701b421f))

#### Paragraph 1

PubMed lists PMID 41389446 in Psychoneuroendocrinology as Journal Article, Systematic Review, with publication-date metadata of 2025-12-05 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41389446-2026-01-27-7275701b421f`](#source-pubmed-observation-pmid-41389446-2026-01-27-7275701b421f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41389446-2026-01-27-7275701b421f`](#source-pubmed-observation-pmid-41389446-2026-01-27-7275701b421f))

### Sources

<a id="source-pubmed-observation-pmid-41389446-2026-01-27-7275701b421f"></a>
- **The active monitoring of oxytocin research evidence (AMORE) platform. · retained source version 1:2026-01-27:current:7275701b421f4b71c71164c21dd699f9565f8a2a680ea7e4b57b56bbfdcd0e49** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41389446/) (`pubmed-observation-pmid-41389446-2026-01-27-7275701b421f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The active monitoring of oxytocin research evidence (AMORE) platform." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41389446-oxytocin-v1 SHA-256: 9b8b0ee974d69f10561f788654c825fa9508c533b4ead56674084dff83bdc548.

---

<a id="pubmed-pmid-41458027-oxytocin-v1"></a>

## How factors of the therapeutic alliance interact with oxytocin neurotransmission in psychotherapy.

> PubMed lists PMID 41458027 in Frontiers in psychiatry as Journal Article, Review, with publication-date metadata of 2025-12-11 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41458027-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-12-31
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41458027-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41458027-oxytocin-v1
- Content SHA-256: `261b655026d9cc4c18e085b022a2a966ecddcf9e6113dfbeb6f3da770608aa87`

### Claims and source pins

#### Headline

How factors of the therapeutic alliance interact with oxytocin neurotransmission in psychotherapy. ([`pubmed-observation-pmid-41458027-2025-12-31-20ba9ea2d96b`](#source-pubmed-observation-pmid-41458027-2025-12-31-20ba9ea2d96b))

#### Summary

PubMed lists PMID 41458027 in Frontiers in psychiatry as Journal Article, Review, with publication-date metadata of 2025-12-11 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41458027-2025-12-31-20ba9ea2d96b`](#source-pubmed-observation-pmid-41458027-2025-12-31-20ba9ea2d96b))

#### Paragraph 1

PubMed lists PMID 41458027 in Frontiers in psychiatry as Journal Article, Review, with publication-date metadata of 2025-12-11 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41458027-2025-12-31-20ba9ea2d96b`](#source-pubmed-observation-pmid-41458027-2025-12-31-20ba9ea2d96b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41458027-2025-12-31-20ba9ea2d96b`](#source-pubmed-observation-pmid-41458027-2025-12-31-20ba9ea2d96b))

### Sources

<a id="source-pubmed-observation-pmid-41458027-2025-12-31-20ba9ea2d96b"></a>
- **How factors of the therapeutic alliance interact with oxytocin neurotransmission in psychotherapy. · retained source version 1:2025-12-31:current:20ba9ea2d96b810ecc788c39d58e1bdb91280afa192abd71e680a6d9d5983381** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41458027/) (`pubmed-observation-pmid-41458027-2025-12-31-20ba9ea2d96b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "How factors of the therapeutic alliance interact with oxytocin neurotransmission in psychotherapy." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41458027-oxytocin-v1 SHA-256: 261b655026d9cc4c18e085b022a2a966ecddcf9e6113dfbeb6f3da770608aa87.

---

<a id="pubmed-pmid-41503900-oxytocin-v1"></a>

## Current Perspectives on Oxytocin and Alzheimer's Disease-Related Symptoms.

> PubMed lists PMID 41503900 in Current Alzheimer research as Journal Article, Review, with publication-date metadata of 2026 (year precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41503900-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41503900-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41503900-oxytocin-v1
- Content SHA-256: `84cae1bd1120ba2ccf914bdea1cdc99075462870bd1c5f48dd3faa7646099c44`

### Claims and source pins

#### Headline

Current Perspectives on Oxytocin and Alzheimer's Disease-Related Symptoms. ([`pubmed-observation-pmid-41503900-2026-08-21-ef51a42ccd9e`](#source-pubmed-observation-pmid-41503900-2026-08-21-ef51a42ccd9e))

#### Summary

PubMed lists PMID 41503900 in Current Alzheimer research as Journal Article, Review, with publication-date metadata of 2026 (year precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41503900-2026-08-21-ef51a42ccd9e`](#source-pubmed-observation-pmid-41503900-2026-08-21-ef51a42ccd9e))

#### Paragraph 1

PubMed lists PMID 41503900 in Current Alzheimer research as Journal Article, Review, with publication-date metadata of 2026 (year precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41503900-2026-08-21-ef51a42ccd9e`](#source-pubmed-observation-pmid-41503900-2026-08-21-ef51a42ccd9e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41503900-2026-08-21-ef51a42ccd9e`](#source-pubmed-observation-pmid-41503900-2026-08-21-ef51a42ccd9e))

### Sources

<a id="source-pubmed-observation-pmid-41503900-2026-08-21-ef51a42ccd9e"></a>
- **Current Perspectives on Oxytocin and Alzheimer's Disease-Related Symptoms. · retained source version 1:2026-08-21:current:ef51a42ccd9ee53c363ba35d27e3a7a4024c00d41537f906307998c6868bea16** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41503900/) (`pubmed-observation-pmid-41503900-2026-08-21-ef51a42ccd9e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Current Perspectives on Oxytocin and Alzheimer's Disease-Related Symptoms." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41503900-oxytocin-v1 SHA-256: 84cae1bd1120ba2ccf914bdea1cdc99075462870bd1c5f48dd3faa7646099c44.

---

<a id="pubmed-pmid-41619996-oxytocin-v1"></a>

## Oxytocin in chronic pain: From analgesic to biopsychosocial adjuvant - An opinion paper.

> PubMed lists PMID 41619996 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-01-29 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41619996-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41619996-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41619996-oxytocin-v1
- Content SHA-256: `065003f113213f4ee2982ec59432c2313854e312c5a88696dfba75cf37fe3fb2`

### Claims and source pins

#### Headline

Oxytocin in chronic pain: From analgesic to biopsychosocial adjuvant - An opinion paper. ([`pubmed-observation-pmid-41619996-2026-11-03-d9d852776fc7`](#source-pubmed-observation-pmid-41619996-2026-11-03-d9d852776fc7))

#### Summary

PubMed lists PMID 41619996 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-01-29 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41619996-2026-11-03-d9d852776fc7`](#source-pubmed-observation-pmid-41619996-2026-11-03-d9d852776fc7))

#### Paragraph 1

PubMed lists PMID 41619996 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-01-29 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41619996-2026-11-03-d9d852776fc7`](#source-pubmed-observation-pmid-41619996-2026-11-03-d9d852776fc7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41619996-2026-11-03-d9d852776fc7`](#source-pubmed-observation-pmid-41619996-2026-11-03-d9d852776fc7))

### Sources

<a id="source-pubmed-observation-pmid-41619996-2026-11-03-d9d852776fc7"></a>
- **Oxytocin in chronic pain: From analgesic to biopsychosocial adjuvant - An opinion paper. · retained source version 1:2026-11-03:current:d9d852776fc78829ce2d5f3aaa09d7cb8c84b83392e10cd3330a19b06d579469** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41619996/) (`pubmed-observation-pmid-41619996-2026-11-03-d9d852776fc7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Oxytocin in chronic pain: From analgesic to biopsychosocial adjuvant - An opinion paper." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41619996-oxytocin-v1 SHA-256: 065003f113213f4ee2982ec59432c2313854e312c5a88696dfba75cf37fe3fb2.

---

<a id="pubmed-pmid-41666492-oxytocin-v1"></a>

## Oxytocin for chronic pain and acupuncture analgesia.

> PubMed lists PMID 41666492 in Current opinion in pharmacology as Journal Article, Review, with publication-date metadata of 2026-01-20 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41666492-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-07
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41666492-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41666492-oxytocin-v1
- Content SHA-256: `b260519822519dc098fe1cb7828f8ba99eb22f393d56632284345fcf079b3b42`

### Claims and source pins

#### Headline

Oxytocin for chronic pain and acupuncture analgesia. ([`pubmed-observation-pmid-41666492-2026-07-07-ae34dd0acf50`](#source-pubmed-observation-pmid-41666492-2026-07-07-ae34dd0acf50))

#### Summary

PubMed lists PMID 41666492 in Current opinion in pharmacology as Journal Article, Review, with publication-date metadata of 2026-01-20 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41666492-2026-07-07-ae34dd0acf50`](#source-pubmed-observation-pmid-41666492-2026-07-07-ae34dd0acf50))

#### Paragraph 1

PubMed lists PMID 41666492 in Current opinion in pharmacology as Journal Article, Review, with publication-date metadata of 2026-01-20 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41666492-2026-07-07-ae34dd0acf50`](#source-pubmed-observation-pmid-41666492-2026-07-07-ae34dd0acf50))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41666492-2026-07-07-ae34dd0acf50`](#source-pubmed-observation-pmid-41666492-2026-07-07-ae34dd0acf50))

### Sources

<a id="source-pubmed-observation-pmid-41666492-2026-07-07-ae34dd0acf50"></a>
- **Oxytocin for chronic pain and acupuncture analgesia. · retained source version 1:2026-07-07:current:ae34dd0acf50e46465ef50d6104f0d2f9eda5f28510d010199f64b7d864b99d2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41666492/) (`pubmed-observation-pmid-41666492-2026-07-07-ae34dd0acf50`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Oxytocin for chronic pain and acupuncture analgesia." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41666492-oxytocin-v1 SHA-256: b260519822519dc098fe1cb7828f8ba99eb22f393d56632284345fcf079b3b42.

---

<a id="pubmed-pmid-41707759-oxytocin-v1"></a>

## Oxytocin, sex hormones and brain activity in facial expression processing: A sex-based systematic review.

> PubMed lists PMID 41707759 in Neuroscience and biobehavioral reviews as Journal Article, Systematic Review, with publication-date metadata of 2026-02-16 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41707759-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41707759-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41707759-oxytocin-v1
- Content SHA-256: `c800f8a5dcd700a4d6bae92645cbe092d74aae22d521ec19d080c5149fa7ad1a`

### Claims and source pins

#### Headline

Oxytocin, sex hormones and brain activity in facial expression processing: A sex-based systematic review. ([`pubmed-observation-pmid-41707759-2026-11-05-8b8daee549bb`](#source-pubmed-observation-pmid-41707759-2026-11-05-8b8daee549bb))

#### Summary

PubMed lists PMID 41707759 in Neuroscience and biobehavioral reviews as Journal Article, Systematic Review, with publication-date metadata of 2026-02-16 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41707759-2026-11-05-8b8daee549bb`](#source-pubmed-observation-pmid-41707759-2026-11-05-8b8daee549bb))

#### Paragraph 1

PubMed lists PMID 41707759 in Neuroscience and biobehavioral reviews as Journal Article, Systematic Review, with publication-date metadata of 2026-02-16 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41707759-2026-11-05-8b8daee549bb`](#source-pubmed-observation-pmid-41707759-2026-11-05-8b8daee549bb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41707759-2026-11-05-8b8daee549bb`](#source-pubmed-observation-pmid-41707759-2026-11-05-8b8daee549bb))

### Sources

<a id="source-pubmed-observation-pmid-41707759-2026-11-05-8b8daee549bb"></a>
- **Oxytocin, sex hormones and brain activity in facial expression processing: A sex-based systematic review. · retained source version 1:2026-11-05:current:8b8daee549bbeb67239ff84fc8ea0b39341cf79d4b2fbf9ef63491a33f0fc2d0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41707759/) (`pubmed-observation-pmid-41707759-2026-11-05-8b8daee549bb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Oxytocin, sex hormones and brain activity in facial expression processing: A sex-based systematic review." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41707759-oxytocin-v1 SHA-256: c800f8a5dcd700a4d6bae92645cbe092d74aae22d521ec19d080c5149fa7ad1a.

---

<a id="pubmed-pmid-41759439-oxytocin-v1"></a>

## Oxytocin beyond social bonding: Advancing neuromodulation, synaptic plasticity, and epigenetic precision in CNS disorders.

> PubMed lists PMID 41759439 in Neuropeptides as Journal Article, Review, with publication-date metadata of 2026-02-25 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41759439-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41759439-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41759439-oxytocin-v1
- Content SHA-256: `766d0aeea8d004d15f1372b601e3a458a41ef2e3f3f02956e7aed13ee891a3e8`

### Claims and source pins

#### Headline

Oxytocin beyond social bonding: Advancing neuromodulation, synaptic plasticity, and epigenetic precision in CNS disorders. ([`pubmed-observation-pmid-41759439-2026-07-10-dca2943bc6ee`](#source-pubmed-observation-pmid-41759439-2026-07-10-dca2943bc6ee))

#### Summary

PubMed lists PMID 41759439 in Neuropeptides as Journal Article, Review, with publication-date metadata of 2026-02-25 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41759439-2026-07-10-dca2943bc6ee`](#source-pubmed-observation-pmid-41759439-2026-07-10-dca2943bc6ee))

#### Paragraph 1

PubMed lists PMID 41759439 in Neuropeptides as Journal Article, Review, with publication-date metadata of 2026-02-25 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41759439-2026-07-10-dca2943bc6ee`](#source-pubmed-observation-pmid-41759439-2026-07-10-dca2943bc6ee))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41759439-2026-07-10-dca2943bc6ee`](#source-pubmed-observation-pmid-41759439-2026-07-10-dca2943bc6ee))

### Sources

<a id="source-pubmed-observation-pmid-41759439-2026-07-10-dca2943bc6ee"></a>
- **Oxytocin beyond social bonding: Advancing neuromodulation, synaptic plasticity, and epigenetic precision in CNS disorders. · retained source version 1:2026-07-10:current:dca2943bc6ee73dc66c996f67ff04a97716444ada230bb4021dd09ce5dcb940f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41759439/) (`pubmed-observation-pmid-41759439-2026-07-10-dca2943bc6ee`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Oxytocin beyond social bonding: Advancing neuromodulation, synaptic plasticity, and epigenetic precision in CNS disorders." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41759439-oxytocin-v1 SHA-256: 766d0aeea8d004d15f1372b601e3a458a41ef2e3f3f02956e7aed13ee891a3e8.

---

<a id="pubmed-pmid-41776858-oxytocin-v1"></a>

## Oxytocin facilitates top-down and bottom-up attention to emotional faces in a general and temporal-dependent manner.

> PubMed lists PMID 41776858 in Psychological medicine as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-03-04 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41776858-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41776858-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41776858-oxytocin-v1
- Content SHA-256: `9ed77511eed8b8509f06c612d00bd9dc45bb9285728b58c18e1c7cd4c1aa6a25`

### Claims and source pins

#### Headline

Oxytocin facilitates top-down and bottom-up attention to emotional faces in a general and temporal-dependent manner. ([`pubmed-observation-pmid-41776858-2026-09-10-9406d05c8b7a`](#source-pubmed-observation-pmid-41776858-2026-09-10-9406d05c8b7a))

#### Summary

PubMed lists PMID 41776858 in Psychological medicine as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-03-04 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41776858-2026-09-10-9406d05c8b7a`](#source-pubmed-observation-pmid-41776858-2026-09-10-9406d05c8b7a))

#### Paragraph 1

PubMed lists PMID 41776858 in Psychological medicine as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-03-04 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41776858-2026-09-10-9406d05c8b7a`](#source-pubmed-observation-pmid-41776858-2026-09-10-9406d05c8b7a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41776858-2026-09-10-9406d05c8b7a`](#source-pubmed-observation-pmid-41776858-2026-09-10-9406d05c8b7a))

### Sources

<a id="source-pubmed-observation-pmid-41776858-2026-09-10-9406d05c8b7a"></a>
- **Oxytocin facilitates top-down and bottom-up attention to emotional faces in a general and temporal-dependent manner. · retained source version 1:2026-09-10:current:9406d05c8b7ad7f33ce3171ea46a9bf89816469da0b01cb0e9bbf902578a31bb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41776858/) (`pubmed-observation-pmid-41776858-2026-09-10-9406d05c8b7a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Oxytocin facilitates top-down and bottom-up attention to emotional faces in a general and temporal-dependent manner." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41776858-oxytocin-v1 SHA-256: 9ed77511eed8b8509f06c612d00bd9dc45bb9285728b58c18e1c7cd4c1aa6a25.

---

<a id="pubmed-pmid-41796877-oxytocin-v1"></a>

## Rewiring connection: The role of oxytocin in interactive media behavior.

> PubMed lists PMID 41796877 in Neuroscience and biobehavioral reviews as Journal Article, Review, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41796877-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41796877-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41796877-oxytocin-v1
- Content SHA-256: `bdeabf3b55ca3ddb6ec5e72eece4c799f25f5acc06cbe9c02749615ba5c7b9a3`

### Claims and source pins

#### Headline

Rewiring connection: The role of oxytocin in interactive media behavior. ([`pubmed-observation-pmid-41796877-2026-11-05-9f4d36628089`](#source-pubmed-observation-pmid-41796877-2026-11-05-9f4d36628089))

#### Summary

PubMed lists PMID 41796877 in Neuroscience and biobehavioral reviews as Journal Article, Review, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41796877-2026-11-05-9f4d36628089`](#source-pubmed-observation-pmid-41796877-2026-11-05-9f4d36628089))

#### Paragraph 1

PubMed lists PMID 41796877 in Neuroscience and biobehavioral reviews as Journal Article, Review, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41796877-2026-11-05-9f4d36628089`](#source-pubmed-observation-pmid-41796877-2026-11-05-9f4d36628089))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41796877-2026-11-05-9f4d36628089`](#source-pubmed-observation-pmid-41796877-2026-11-05-9f4d36628089))

### Sources

<a id="source-pubmed-observation-pmid-41796877-2026-11-05-9f4d36628089"></a>
- **Rewiring connection: The role of oxytocin in interactive media behavior. · retained source version 1:2026-11-05:current:9f4d366280899fa82816b564ca8d4a065ad6cbf15c459f68293b3cad22c30f32** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41796877/) (`pubmed-observation-pmid-41796877-2026-11-05-9f4d36628089`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Rewiring connection: The role of oxytocin in interactive media behavior." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41796877-oxytocin-v1 SHA-256: bdeabf3b55ca3ddb6ec5e72eece4c799f25f5acc06cbe9c02749615ba5c7b9a3.

---

<a id="pubmed-pmid-41796879-oxytocin-v1"></a>

## Reframing oxytocin as a behavioral flexibility hormone.

> PubMed lists PMID 41796879 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41796879-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41796879-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41796879-oxytocin-v1
- Content SHA-256: `329de1feb561977a78f19a36129bd4834dee94d8d4c222316c8f3913e383a596`

### Claims and source pins

#### Headline

Reframing oxytocin as a behavioral flexibility hormone. ([`pubmed-observation-pmid-41796879-2026-11-05-e444d28eac79`](#source-pubmed-observation-pmid-41796879-2026-11-05-e444d28eac79))

#### Summary

PubMed lists PMID 41796879 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41796879-2026-11-05-e444d28eac79`](#source-pubmed-observation-pmid-41796879-2026-11-05-e444d28eac79))

#### Paragraph 1

PubMed lists PMID 41796879 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41796879-2026-11-05-e444d28eac79`](#source-pubmed-observation-pmid-41796879-2026-11-05-e444d28eac79))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41796879-2026-11-05-e444d28eac79`](#source-pubmed-observation-pmid-41796879-2026-11-05-e444d28eac79))

### Sources

<a id="source-pubmed-observation-pmid-41796879-2026-11-05-e444d28eac79"></a>
- **Reframing oxytocin as a behavioral flexibility hormone. · retained source version 1:2026-11-05:current:e444d28eac7951159926e9979ef432b19159eaa090537d779852ce4a9392ce1f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41796879/) (`pubmed-observation-pmid-41796879-2026-11-05-e444d28eac79`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Reframing oxytocin as a behavioral flexibility hormone." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41796879-oxytocin-v1 SHA-256: 329de1feb561977a78f19a36129bd4834dee94d8d4c222316c8f3913e383a596.

---

<a id="pubmed-pmid-41903260-oxytocin-v1"></a>

## An epigenetic framework for understanding contextual influences on neural and socio-emotional development: Narrative review and case-study of the oxytocin receptor.

> PubMed lists PMID 41903260 in Developmental cognitive neuroscience as Journal Article, Review, with publication-date metadata of 2026-03-20 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41903260-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41903260-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41903260-oxytocin-v1
- Content SHA-256: `5c053b2ab87c0ffdfc2681a027112348ae93f0672000491eeb9a1ef3ea167ea6`

### Claims and source pins

#### Headline

An epigenetic framework for understanding contextual influences on neural and socio-emotional development: Narrative review and case-study of the oxytocin receptor. ([`pubmed-observation-pmid-41903260-2026-08-13-3e47920df091`](#source-pubmed-observation-pmid-41903260-2026-08-13-3e47920df091))

#### Summary

PubMed lists PMID 41903260 in Developmental cognitive neuroscience as Journal Article, Review, with publication-date metadata of 2026-03-20 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41903260-2026-08-13-3e47920df091`](#source-pubmed-observation-pmid-41903260-2026-08-13-3e47920df091))

#### Paragraph 1

PubMed lists PMID 41903260 in Developmental cognitive neuroscience as Journal Article, Review, with publication-date metadata of 2026-03-20 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41903260-2026-08-13-3e47920df091`](#source-pubmed-observation-pmid-41903260-2026-08-13-3e47920df091))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41903260-2026-08-13-3e47920df091`](#source-pubmed-observation-pmid-41903260-2026-08-13-3e47920df091))

### Sources

<a id="source-pubmed-observation-pmid-41903260-2026-08-13-3e47920df091"></a>
- **An epigenetic framework for understanding contextual influences on neural and socio-emotional development: Narrative review and case-study of the oxytocin receptor. · retained source version 1:2026-08-13:current:3e47920df091609d8234395493fd9596db3368ed0d5e55fe89325d23e89f7f67** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41903260/) (`pubmed-observation-pmid-41903260-2026-08-13-3e47920df091`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "An epigenetic framework for understanding contextual influences on neural and socio-emotional development: Narrative review and case-study of the oxytocin receptor." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41903260-oxytocin-v1 SHA-256: 5c053b2ab87c0ffdfc2681a027112348ae93f0672000491eeb9a1ef3ea167ea6.

---

<a id="pubmed-pmid-41989096-oxytocin-v1"></a>

## \[Boosting oxytocin in postpartum depression\].

> PubMed lists PMID 41989096 in Nederlands tijdschrift voor geneeskunde as Journal Article, Randomized Controlled Trial, English Abstract, with publication-date metadata of 2026-04-16 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41989096-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41989096-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41989096-oxytocin-v1
- Content SHA-256: `80bdf9442c41573b4dbc61375eb97bc87eb581b5e188ad272f84e90e1ee4ef88`

### Claims and source pins

#### Headline

\[Boosting oxytocin in postpartum depression\]. ([`pubmed-observation-pmid-41989096-2026-08-12-8221c7cc1c8a`](#source-pubmed-observation-pmid-41989096-2026-08-12-8221c7cc1c8a))

#### Summary

PubMed lists PMID 41989096 in Nederlands tijdschrift voor geneeskunde as Journal Article, Randomized Controlled Trial, English Abstract, with publication-date metadata of 2026-04-16 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41989096-2026-08-12-8221c7cc1c8a`](#source-pubmed-observation-pmid-41989096-2026-08-12-8221c7cc1c8a))

#### Paragraph 1

PubMed lists PMID 41989096 in Nederlands tijdschrift voor geneeskunde as Journal Article, Randomized Controlled Trial, English Abstract, with publication-date metadata of 2026-04-16 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41989096-2026-08-12-8221c7cc1c8a`](#source-pubmed-observation-pmid-41989096-2026-08-12-8221c7cc1c8a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41989096-2026-08-12-8221c7cc1c8a`](#source-pubmed-observation-pmid-41989096-2026-08-12-8221c7cc1c8a))

### Sources

<a id="source-pubmed-observation-pmid-41989096-2026-08-12-8221c7cc1c8a"></a>
- **\[Boosting oxytocin in postpartum depression\]. · retained source version 1:2026-08-12:current:8221c7cc1c8a153f27a2f71777a1f9d19cf15764e8444ead080e02cdc382cfd8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41989096/) (`pubmed-observation-pmid-41989096-2026-08-12-8221c7cc1c8a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Boosting oxytocin in postpartum depression\]." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-41989096-oxytocin-v1 SHA-256: 80bdf9442c41573b4dbc61375eb97bc87eb581b5e188ad272f84e90e1ee4ef88.

---

<a id="pubmed-pmid-42002246-oxytocin-v1"></a>

## Beyond lactation: Central oxytocin in maternal mental health and disease.

> PubMed lists PMID 42002246 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42002246-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42002246-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42002246-oxytocin-v1
- Content SHA-256: `51a450ee769860f84001d3fd0316db33b7ada917615e7e07a242e446ee20ce19`

### Claims and source pins

#### Headline

Beyond lactation: Central oxytocin in maternal mental health and disease. ([`pubmed-observation-pmid-42002246-2026-11-06-95f2bef52da4`](#source-pubmed-observation-pmid-42002246-2026-11-06-95f2bef52da4))

#### Summary

PubMed lists PMID 42002246 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42002246-2026-11-06-95f2bef52da4`](#source-pubmed-observation-pmid-42002246-2026-11-06-95f2bef52da4))

#### Paragraph 1

PubMed lists PMID 42002246 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42002246-2026-11-06-95f2bef52da4`](#source-pubmed-observation-pmid-42002246-2026-11-06-95f2bef52da4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42002246-2026-11-06-95f2bef52da4`](#source-pubmed-observation-pmid-42002246-2026-11-06-95f2bef52da4))

### Sources

<a id="source-pubmed-observation-pmid-42002246-2026-11-06-95f2bef52da4"></a>
- **Beyond lactation: Central oxytocin in maternal mental health and disease. · retained source version 1:2026-11-06:current:95f2bef52da4e770120dca33637e2175702872dac3ee7f1ef0cdb62855e712d9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42002246/) (`pubmed-observation-pmid-42002246-2026-11-06-95f2bef52da4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Beyond lactation: Central oxytocin in maternal mental health and disease." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42002246-oxytocin-v1 SHA-256: 51a450ee769860f84001d3fd0316db33b7ada917615e7e07a242e446ee20ce19.

---

<a id="pubmed-pmid-42093825-oxytocin-v1"></a>

## A narrative review on oxytocin at the intersection of sleep, stress, and social behavior.

> PubMed lists PMID 42093825 in Frontiers in neuroscience as Journal Article, Review, with publication-date metadata of 2026-04-21 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42093825-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42093825-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42093825-oxytocin-v1
- Content SHA-256: `794b2b87b2be32cf38ed47ea9e505d3d209d136136ea5517edc4bf9c798e685a`

### Claims and source pins

#### Headline

A narrative review on oxytocin at the intersection of sleep, stress, and social behavior. ([`pubmed-observation-pmid-42093825-2026-11-05-1425831914fe`](#source-pubmed-observation-pmid-42093825-2026-11-05-1425831914fe))

#### Summary

PubMed lists PMID 42093825 in Frontiers in neuroscience as Journal Article, Review, with publication-date metadata of 2026-04-21 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42093825-2026-11-05-1425831914fe`](#source-pubmed-observation-pmid-42093825-2026-11-05-1425831914fe))

#### Paragraph 1

PubMed lists PMID 42093825 in Frontiers in neuroscience as Journal Article, Review, with publication-date metadata of 2026-04-21 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42093825-2026-11-05-1425831914fe`](#source-pubmed-observation-pmid-42093825-2026-11-05-1425831914fe))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42093825-2026-11-05-1425831914fe`](#source-pubmed-observation-pmid-42093825-2026-11-05-1425831914fe))

### Sources

<a id="source-pubmed-observation-pmid-42093825-2026-11-05-1425831914fe"></a>
- **A narrative review on oxytocin at the intersection of sleep, stress, and social behavior. · retained source version 1:2026-11-05:current:1425831914fec2bf869c48492059500e986d08d29fb88b5f1209556a548370d3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42093825/) (`pubmed-observation-pmid-42093825-2026-11-05-1425831914fe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A narrative review on oxytocin at the intersection of sleep, stress, and social behavior." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42093825-oxytocin-v1 SHA-256: 794b2b87b2be32cf38ed47ea9e505d3d209d136136ea5517edc4bf9c798e685a.

---

<a id="pubmed-pmid-42126578-oxytocin-v1"></a>

## Early life adversity, oxytocin system alterations, and addiction vulnerability: a narrative review.

> PubMed lists PMID 42126578 in Psychopharmacology as Journal Article, Review, with publication-date metadata of 2026-05-13 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42126578-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42126578-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42126578-oxytocin-v1
- Content SHA-256: `e46e98be97b760e845f0b8da5f06da2cc7d6d844056eeb0ddbbaca69d7b5494a`

### Claims and source pins

#### Headline

Early life adversity, oxytocin system alterations, and addiction vulnerability: a narrative review. ([`pubmed-observation-pmid-42126578-2026-05-13-90831899df77`](#source-pubmed-observation-pmid-42126578-2026-05-13-90831899df77))

#### Summary

PubMed lists PMID 42126578 in Psychopharmacology as Journal Article, Review, with publication-date metadata of 2026-05-13 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42126578-2026-05-13-90831899df77`](#source-pubmed-observation-pmid-42126578-2026-05-13-90831899df77))

#### Paragraph 1

PubMed lists PMID 42126578 in Psychopharmacology as Journal Article, Review, with publication-date metadata of 2026-05-13 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42126578-2026-05-13-90831899df77`](#source-pubmed-observation-pmid-42126578-2026-05-13-90831899df77))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42126578-2026-05-13-90831899df77`](#source-pubmed-observation-pmid-42126578-2026-05-13-90831899df77))

### Sources

<a id="source-pubmed-observation-pmid-42126578-2026-05-13-90831899df77"></a>
- **Early life adversity, oxytocin system alterations, and addiction vulnerability: a narrative review. · retained source version 1:2026-05-13:current:90831899df772afb71ee70bda54a7b39cd613bd9e144c224e902e4e670d6f213** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42126578/) (`pubmed-observation-pmid-42126578-2026-05-13-90831899df77`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Early life adversity, oxytocin system alterations, and addiction vulnerability: a narrative review." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42126578-oxytocin-v1 SHA-256: e46e98be97b760e845f0b8da5f06da2cc7d6d844056eeb0ddbbaca69d7b5494a.

---

<a id="pubmed-pmid-42144048-oxytocin-v1"></a>

## Oxytocin and autism - A precision medicine framework to unpack mechanisms and evidence.

> PubMed lists PMID 42144048 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-16 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42144048-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42144048-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42144048-oxytocin-v1
- Content SHA-256: `8e4088684993f5b05b3e657a8f826dd8e75111b173878bd0fc6e6a6e166c175f`

### Claims and source pins

#### Headline

Oxytocin and autism - A precision medicine framework to unpack mechanisms and evidence. ([`pubmed-observation-pmid-42144048-2026-11-08-0f236e06992a`](#source-pubmed-observation-pmid-42144048-2026-11-08-0f236e06992a))

#### Summary

PubMed lists PMID 42144048 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-16 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42144048-2026-11-08-0f236e06992a`](#source-pubmed-observation-pmid-42144048-2026-11-08-0f236e06992a))

#### Paragraph 1

PubMed lists PMID 42144048 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-16 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42144048-2026-11-08-0f236e06992a`](#source-pubmed-observation-pmid-42144048-2026-11-08-0f236e06992a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42144048-2026-11-08-0f236e06992a`](#source-pubmed-observation-pmid-42144048-2026-11-08-0f236e06992a))

### Sources

<a id="source-pubmed-observation-pmid-42144048-2026-11-08-0f236e06992a"></a>
- **Oxytocin and autism - A precision medicine framework to unpack mechanisms and evidence. · retained source version 1:2026-11-08:current:0f236e06992a619ce323bc6f56330c02c8b99a6a782588375e9b28ef025b04d4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42144048/) (`pubmed-observation-pmid-42144048-2026-11-08-0f236e06992a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Oxytocin and autism - A precision medicine framework to unpack mechanisms and evidence." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42144048-oxytocin-v1 SHA-256: 8e4088684993f5b05b3e657a8f826dd8e75111b173878bd0fc6e6a6e166c175f.

---

<a id="pubmed-pmid-42191115-oxytocin-v1"></a>

## Oxytocin and social neuroscience - sexually dimorphic OXTR neurons in mouse preoptic area.

> PubMed lists PMID 42191115 in Progress in neurobiology as Journal Article, Review, with publication-date metadata of 2026-05-25 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42191115-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42191115-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42191115-oxytocin-v1
- Content SHA-256: `45e0e0fb1e9e162b4ee754292ef7111d3c787edc2b55d282ce1fb80da0684be7`

### Claims and source pins

#### Headline

Oxytocin and social neuroscience - sexually dimorphic OXTR neurons in mouse preoptic area. ([`pubmed-observation-pmid-42191115-2026-11-12-ae7805db91a6`](#source-pubmed-observation-pmid-42191115-2026-11-12-ae7805db91a6))

#### Summary

PubMed lists PMID 42191115 in Progress in neurobiology as Journal Article, Review, with publication-date metadata of 2026-05-25 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42191115-2026-11-12-ae7805db91a6`](#source-pubmed-observation-pmid-42191115-2026-11-12-ae7805db91a6))

#### Paragraph 1

PubMed lists PMID 42191115 in Progress in neurobiology as Journal Article, Review, with publication-date metadata of 2026-05-25 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42191115-2026-11-12-ae7805db91a6`](#source-pubmed-observation-pmid-42191115-2026-11-12-ae7805db91a6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42191115-2026-11-12-ae7805db91a6`](#source-pubmed-observation-pmid-42191115-2026-11-12-ae7805db91a6))

### Sources

<a id="source-pubmed-observation-pmid-42191115-2026-11-12-ae7805db91a6"></a>
- **Oxytocin and social neuroscience - sexually dimorphic OXTR neurons in mouse preoptic area. · retained source version 1:2026-11-12:current:ae7805db91a6db580754a0c9aa1fc046c957d4908c62d80bcc4532869590b69c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42191115/) (`pubmed-observation-pmid-42191115-2026-11-12-ae7805db91a6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Oxytocin and social neuroscience - sexually dimorphic OXTR neurons in mouse preoptic area." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42191115-oxytocin-v1 SHA-256: 45e0e0fb1e9e162b4ee754292ef7111d3c787edc2b55d282ce1fb80da0684be7.

---

<a id="pubmed-pmid-42236472-oxytocin-v1"></a>

## Translational pathways of oxytocin therapy in schizophrenia: bridging negative symptom domains and neural mechanisms.

> PubMed lists PMID 42236472 in Translational psychiatry as Journal Article, Review, with publication-date metadata of 2026-06-03 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42236472-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42236472-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42236472-oxytocin-v1
- Content SHA-256: `81eaeb82ff1e5b5b04b1f2226d9d5fad692f06527c22a57ddab1e12860369219`

### Claims and source pins

#### Headline

Translational pathways of oxytocin therapy in schizophrenia: bridging negative symptom domains and neural mechanisms. ([`pubmed-observation-pmid-42236472-2026-08-13-c3cee32ba9a5`](#source-pubmed-observation-pmid-42236472-2026-08-13-c3cee32ba9a5))

#### Summary

PubMed lists PMID 42236472 in Translational psychiatry as Journal Article, Review, with publication-date metadata of 2026-06-03 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42236472-2026-08-13-c3cee32ba9a5`](#source-pubmed-observation-pmid-42236472-2026-08-13-c3cee32ba9a5))

#### Paragraph 1

PubMed lists PMID 42236472 in Translational psychiatry as Journal Article, Review, with publication-date metadata of 2026-06-03 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42236472-2026-08-13-c3cee32ba9a5`](#source-pubmed-observation-pmid-42236472-2026-08-13-c3cee32ba9a5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42236472-2026-08-13-c3cee32ba9a5`](#source-pubmed-observation-pmid-42236472-2026-08-13-c3cee32ba9a5))

### Sources

<a id="source-pubmed-observation-pmid-42236472-2026-08-13-c3cee32ba9a5"></a>
- **Translational pathways of oxytocin therapy in schizophrenia: bridging negative symptom domains and neural mechanisms. · retained source version 1:2026-08-13:current:c3cee32ba9a527a190b31516332ffb07c7b7d495e192d6b44e9974f383201d3a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42236472/) (`pubmed-observation-pmid-42236472-2026-08-13-c3cee32ba9a5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Translational pathways of oxytocin therapy in schizophrenia: bridging negative symptom domains and neural mechanisms." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42236472-oxytocin-v1 SHA-256: 81eaeb82ff1e5b5b04b1f2226d9d5fad692f06527c22a57ddab1e12860369219.

---

<a id="pubmed-pmid-42415063-oxytocin-v1"></a>

## Oxytocin and RAGE signaling at the intersection of social neurodevelopment and inflammation.

> PubMed lists PMID 42415063 in Journal of translational medicine as Journal Article, Review, with publication-date metadata of 2026-07-07 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42415063-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42415063-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42415063-oxytocin-v1
- Content SHA-256: `e6d45ead4cf54fd55633d914c949e1c16fb41a1022dfa1ef15d5ae45ab4d2e7b`

### Claims and source pins

#### Headline

Oxytocin and RAGE signaling at the intersection of social neurodevelopment and inflammation. ([`pubmed-observation-pmid-42415063-2026-10-03-30145c821b91`](#source-pubmed-observation-pmid-42415063-2026-10-03-30145c821b91))

#### Summary

PubMed lists PMID 42415063 in Journal of translational medicine as Journal Article, Review, with publication-date metadata of 2026-07-07 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42415063-2026-10-03-30145c821b91`](#source-pubmed-observation-pmid-42415063-2026-10-03-30145c821b91))

#### Paragraph 1

PubMed lists PMID 42415063 in Journal of translational medicine as Journal Article, Review, with publication-date metadata of 2026-07-07 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42415063-2026-10-03-30145c821b91`](#source-pubmed-observation-pmid-42415063-2026-10-03-30145c821b91))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42415063-2026-10-03-30145c821b91`](#source-pubmed-observation-pmid-42415063-2026-10-03-30145c821b91))

### Sources

<a id="source-pubmed-observation-pmid-42415063-2026-10-03-30145c821b91"></a>
- **Oxytocin and RAGE signaling at the intersection of social neurodevelopment and inflammation. · retained source version 1:2026-10-03:current:30145c821b91369c3f8965899179dabb4c5f944f735e88dc30d353cd63dd13f4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42415063/) (`pubmed-observation-pmid-42415063-2026-10-03-30145c821b91`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Oxytocin and RAGE signaling at the intersection of social neurodevelopment and inflammation." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42415063-oxytocin-v1 SHA-256: e6d45ead4cf54fd55633d914c949e1c16fb41a1022dfa1ef15d5ae45ab4d2e7b.

---

<a id="pubmed-pmid-42623778-oxytocin-v1"></a>

## Anterior cingulate cortex, anterior insular cortex and altruistic behaviors; a hypothetical role for oxytocin.

> PubMed lists PMID 42623778 in Hormones and behavior as Journal Article, Review, with publication-date metadata of 2026-08-20 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42623778-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42623778-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42623778-oxytocin-v1
- Content SHA-256: `2219f7bcb575043364b4406aad2880391a5d5bd8cc795048b8f99aa4ac1a782e`

### Claims and source pins

#### Headline

Anterior cingulate cortex, anterior insular cortex and altruistic behaviors; a hypothetical role for oxytocin. ([`pubmed-observation-pmid-42623778-2026-09-03-60f074ba525c`](#source-pubmed-observation-pmid-42623778-2026-09-03-60f074ba525c))

#### Summary

PubMed lists PMID 42623778 in Hormones and behavior as Journal Article, Review, with publication-date metadata of 2026-08-20 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42623778-2026-09-03-60f074ba525c`](#source-pubmed-observation-pmid-42623778-2026-09-03-60f074ba525c))

#### Paragraph 1

PubMed lists PMID 42623778 in Hormones and behavior as Journal Article, Review, with publication-date metadata of 2026-08-20 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42623778-2026-09-03-60f074ba525c`](#source-pubmed-observation-pmid-42623778-2026-09-03-60f074ba525c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42623778-2026-09-03-60f074ba525c`](#source-pubmed-observation-pmid-42623778-2026-09-03-60f074ba525c))

### Sources

<a id="source-pubmed-observation-pmid-42623778-2026-09-03-60f074ba525c"></a>
- **Anterior cingulate cortex, anterior insular cortex and altruistic behaviors; a hypothetical role for oxytocin. · retained source version 1:2026-09-03:current:60f074ba525c4e21d940d669720d48c729e8449b0bbbab054fa0280fa5805abb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42623778/) (`pubmed-observation-pmid-42623778-2026-09-03-60f074ba525c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Anterior cingulate cortex, anterior insular cortex and altruistic behaviors; a hypothetical role for oxytocin." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42623778-oxytocin-v1 SHA-256: 2219f7bcb575043364b4406aad2880391a5d5bd8cc795048b8f99aa4ac1a782e.

---

<a id="pubmed-pmid-42716459-oxytocin-v1"></a>

## Markers of the maternal oxytocin system and mother-infant bonding during the first postpartum year.

> PubMed lists PMID 42716459 in Progress in neurobiology as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2026-09-09 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42716459-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42716459-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42716459-oxytocin-v1
- Content SHA-256: `806a251fc82a65b4394030a0889ce71682c50864eb1ecb32cc748595e3f099b4`

### Claims and source pins

#### Headline

Markers of the maternal oxytocin system and mother-infant bonding during the first postpartum year. ([`pubmed-observation-pmid-42716459-2026-10-14-0f17f8ece999`](#source-pubmed-observation-pmid-42716459-2026-10-14-0f17f8ece999))

#### Summary

PubMed lists PMID 42716459 in Progress in neurobiology as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2026-09-09 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42716459-2026-10-14-0f17f8ece999`](#source-pubmed-observation-pmid-42716459-2026-10-14-0f17f8ece999))

#### Paragraph 1

PubMed lists PMID 42716459 in Progress in neurobiology as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2026-09-09 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42716459-2026-10-14-0f17f8ece999`](#source-pubmed-observation-pmid-42716459-2026-10-14-0f17f8ece999))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42716459-2026-10-14-0f17f8ece999`](#source-pubmed-observation-pmid-42716459-2026-10-14-0f17f8ece999))

### Sources

<a id="source-pubmed-observation-pmid-42716459-2026-10-14-0f17f8ece999"></a>
- **Markers of the maternal oxytocin system and mother-infant bonding during the first postpartum year. · retained source version 1:2026-10-14:current:0f17f8ece999e9ff4d8c333d12f6d6f61ad050176a7acd8eb25a94e1862c8bd6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42716459/) (`pubmed-observation-pmid-42716459-2026-10-14-0f17f8ece999`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Markers of the maternal oxytocin system and mother-infant bonding during the first postpartum year." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42716459-oxytocin-v1 SHA-256: 806a251fc82a65b4394030a0889ce71682c50864eb1ecb32cc748595e3f099b4.

---

<a id="pubmed-pmid-42766066-oxytocin-v1"></a>

## Role of Oxytocin in Obesity.

> PubMed lists PMID 42766066 in Current diabetes reports as Journal Article, Review, with publication-date metadata of 2026-09-21 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42766066-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42766066-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42766066-oxytocin-v1
- Content SHA-256: `dc1c6f5ca9151fcea73d5768acbdc0ff2557c38c2bec27cceda4527c79830a5a`

### Claims and source pins

#### Headline

Role of Oxytocin in Obesity. ([`pubmed-observation-pmid-42766066-2026-11-05-ef7bc1152f85`](#source-pubmed-observation-pmid-42766066-2026-11-05-ef7bc1152f85))

#### Summary

PubMed lists PMID 42766066 in Current diabetes reports as Journal Article, Review, with publication-date metadata of 2026-09-21 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42766066-2026-11-05-ef7bc1152f85`](#source-pubmed-observation-pmid-42766066-2026-11-05-ef7bc1152f85))

#### Paragraph 1

PubMed lists PMID 42766066 in Current diabetes reports as Journal Article, Review, with publication-date metadata of 2026-09-21 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42766066-2026-11-05-ef7bc1152f85`](#source-pubmed-observation-pmid-42766066-2026-11-05-ef7bc1152f85))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42766066-2026-11-05-ef7bc1152f85`](#source-pubmed-observation-pmid-42766066-2026-11-05-ef7bc1152f85))

### Sources

<a id="source-pubmed-observation-pmid-42766066-2026-11-05-ef7bc1152f85"></a>
- **Role of Oxytocin in Obesity. · retained source version 1:2026-11-05:current:ef7bc1152f85bd5e55854817f1a1fa76f2e77ce8f03550f71442b345f2dc49b9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42766066/) (`pubmed-observation-pmid-42766066-2026-11-05-ef7bc1152f85`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Role of Oxytocin in Obesity." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42766066-oxytocin-v1 SHA-256: dc1c6f5ca9151fcea73d5768acbdc0ff2557c38c2bec27cceda4527c79830a5a.

---

<a id="pubmed-pmid-42799216-oxytocin-v1"></a>

## Endometrial Preparation Strategies for Frozen Embryo Transfer in Women with Adenomyosis: A Systematic Review of Hormone Replacement Therapy, Gonadotropin-Releasing Hormone Agonist, and Oxytocin Antag…

> PubMed lists PMID 42799216 in International journal of women's health as Journal Article, Review, with publication-date metadata of 2026-09-21 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42799216-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42799216-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42799216-oxytocin-v1
- Content SHA-256: `23594cd4ac1c37013808551dce52213bcc2d65418ac9e2486271644d665a5a36`

### Claims and source pins

#### Headline

Endometrial Preparation Strategies for Frozen Embryo Transfer in Women with Adenomyosis: A Systematic Review of Hormone Replacement Therapy, Gonadotropin-Releasing Hormone Agonist, and Oxytocin Antag… ([`pubmed-observation-pmid-42799216-2026-09-28-7544b7ff4bdb`](#source-pubmed-observation-pmid-42799216-2026-09-28-7544b7ff4bdb))

#### Summary

PubMed lists PMID 42799216 in International journal of women's health as Journal Article, Review, with publication-date metadata of 2026-09-21 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42799216-2026-09-28-7544b7ff4bdb`](#source-pubmed-observation-pmid-42799216-2026-09-28-7544b7ff4bdb))

#### Paragraph 1

PubMed lists PMID 42799216 in International journal of women's health as Journal Article, Review, with publication-date metadata of 2026-09-21 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42799216-2026-09-28-7544b7ff4bdb`](#source-pubmed-observation-pmid-42799216-2026-09-28-7544b7ff4bdb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42799216-2026-09-28-7544b7ff4bdb`](#source-pubmed-observation-pmid-42799216-2026-09-28-7544b7ff4bdb))

### Sources

<a id="source-pubmed-observation-pmid-42799216-2026-09-28-7544b7ff4bdb"></a>
- **Endometrial Preparation Strategies for Frozen Embryo Transfer in Women with Adenomyosis: A Systematic Review of Hormone Replacement Therapy, Gonadotropin-Releasing Hormone Agonist, and Oxytocin Antagonists. · retained source version 1:2026-09-28:current:7544b7ff4bdb8de072bb96fae85d32789b95c56bb7698770cac127eb5a01cce5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42799216/) (`pubmed-observation-pmid-42799216-2026-09-28-7544b7ff4bdb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Endometrial Preparation Strategies for Frozen Embryo Transfer in Women with Adenomyosis: A Systematic Review of Hormone Replacement Therapy, Gonadotropin-Releasing Hormone Agonist, and Oxytocin Antag…." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42799216-oxytocin-v1 SHA-256: 23594cd4ac1c37013808551dce52213bcc2d65418ac9e2486271644d665a5a36.

---

<a id="pubmed-pmid-42876328-oxytocin-v1"></a>

## Opioids and the oxytocin system: Mechanistic interactions altering maternal neuroplasticity.

> PubMed lists PMID 42876328 in Journal of neuroendocrinology as Journal Article, Review, with publication-date metadata of 2026-10 (month precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42876328-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-31
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42876328-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42876328-oxytocin-v1
- Content SHA-256: `32865673bf28dfcdd1f4c2c799cac0a35e5c37735904d72e5cbc476c01f6488b`

### Claims and source pins

#### Headline

Opioids and the oxytocin system: Mechanistic interactions altering maternal neuroplasticity. ([`pubmed-observation-pmid-42876328-2026-10-31-3500e4005645`](#source-pubmed-observation-pmid-42876328-2026-10-31-3500e4005645))

#### Summary

PubMed lists PMID 42876328 in Journal of neuroendocrinology as Journal Article, Review, with publication-date metadata of 2026-10 (month precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42876328-2026-10-31-3500e4005645`](#source-pubmed-observation-pmid-42876328-2026-10-31-3500e4005645))

#### Paragraph 1

PubMed lists PMID 42876328 in Journal of neuroendocrinology as Journal Article, Review, with publication-date metadata of 2026-10 (month precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42876328-2026-10-31-3500e4005645`](#source-pubmed-observation-pmid-42876328-2026-10-31-3500e4005645))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42876328-2026-10-31-3500e4005645`](#source-pubmed-observation-pmid-42876328-2026-10-31-3500e4005645))

### Sources

<a id="source-pubmed-observation-pmid-42876328-2026-10-31-3500e4005645"></a>
- **Opioids and the oxytocin system: Mechanistic interactions altering maternal neuroplasticity. · retained source version 1:2026-10-31:current:3500e400564591a7be039dd27dffd91da7589ebc2c1823459d062f1272095591** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42876328/) (`pubmed-observation-pmid-42876328-2026-10-31-3500e4005645`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Opioids and the oxytocin system: Mechanistic interactions altering maternal neuroplasticity." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42876328-oxytocin-v1 SHA-256: 32865673bf28dfcdd1f4c2c799cac0a35e5c37735904d72e5cbc476c01f6488b.

---

<a id="pubmed-pmid-42903669-oxytocin-v1"></a>

## Context-dependent oxytocin receptor signaling: from molecular architecture to transcript-level receptor engineering.

> PubMed lists PMID 42903669 in Frontiers in neuroscience as Journal Article, Review, with publication-date metadata of 2026-10-06 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42903669-oxytocin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42903669-oxytocin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42903669-oxytocin-v1
- Content SHA-256: `5eaf89b6b12a81cfa0cf71e876f5fe1ed5336e61825a73ed0d4e473e4af31bb7`

### Claims and source pins

#### Headline

Context-dependent oxytocin receptor signaling: from molecular architecture to transcript-level receptor engineering. ([`pubmed-observation-pmid-42903669-2026-10-24-d8cde4e74590`](#source-pubmed-observation-pmid-42903669-2026-10-24-d8cde4e74590))

#### Summary

PubMed lists PMID 42903669 in Frontiers in neuroscience as Journal Article, Review, with publication-date metadata of 2026-10-06 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42903669-2026-10-24-d8cde4e74590`](#source-pubmed-observation-pmid-42903669-2026-10-24-d8cde4e74590))

#### Paragraph 1

PubMed lists PMID 42903669 in Frontiers in neuroscience as Journal Article, Review, with publication-date metadata of 2026-10-06 (day precision). PeptideScanner associated the retained record with the identity slug oxytocin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42903669-2026-10-24-d8cde4e74590`](#source-pubmed-observation-pmid-42903669-2026-10-24-d8cde4e74590))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42903669-2026-10-24-d8cde4e74590`](#source-pubmed-observation-pmid-42903669-2026-10-24-d8cde4e74590))

### Sources

<a id="source-pubmed-observation-pmid-42903669-2026-10-24-d8cde4e74590"></a>
- **Context-dependent oxytocin receptor signaling: from molecular architecture to transcript-level receptor engineering. · retained source version 1:2026-10-24:current:d8cde4e7459007c8f4f43244aff46eb172fc458b72c0b53950036e3b2b642912** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42903669/) (`pubmed-observation-pmid-42903669-2026-10-24-d8cde4e74590`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Context-dependent oxytocin receptor signaling: from molecular architecture to transcript-level receptor engineering." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/oxytocin.json#pubmed-pmid-42903669-oxytocin-v1 SHA-256: 5eaf89b6b12a81cfa0cf71e876f5fe1ed5336e61825a73ed0d4e473e4af31bb7.

